1
|
Ecke TH, Meisl CJ, Schlomm T, Rabien A, Labonté F, Rong D, Hofbauer S, Friedersdorff F, Sommerfeldt L, Gagel N, Gössl A, Barski D, Otto T, Grunewald CM, Niegisch G, Hennig MJP, Kramer MW, Koch S, Roggisch J, Hallmann S, Weiß S, Waldner M, Graff J, Veltrup E, Linden F, Hake R, Eidt S, Wirtz RM. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study. Urol Oncol 2023; 41:484.e17-484.e26. [PMID: 37407421 DOI: 10.1016/j.urolonc.2023.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 06/15/2023] [Accepted: 06/24/2023] [Indexed: 07/07/2023]
Abstract
INTRODUCTION AND OBJECTIVE BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL are urinary-based rapid tests. This multicenter study is the first study comparing all available rapid tests on a large cohort of bladder cancer patients and healthy controls in one setting. METHODS In total 732 urine samples (second morning urine) in a real-world assessment have been analyzed. We evaluated clinical samples from 464 patients with histologically confirmed urothelial tumors of the urinary bladder (17 solitary CIS, 189 low-grade, 187 high-grade nonmuscle invasive, 71 high-grade muscle invasive), 77 patients with No Evidence of Disease (NED), and from 191 healthy controls. Urine samples were analyzed by the BTA stat®, NMP22® BladderChek®, UBC® Rapid Test point-of-care (POC) system using the concile Omega 100 POC reader, and CancerCheck® UBC® rapid VISUAL. Sensitivities and specificities were calculated by contingency analyses. RESULTS All investigated urinary markers detected more pathological concentrations in urine of bladder cancer patients compared to tumor-free patients. The calculated diagnostic sensitivities for BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, and cytology were 62.4%, 13.4%, 58.2%, 28.6%, 36.2% for low-grade, 83.4%, 49.5%, 84.5%, 63.1%, 71.2% for high-grade nonmuscle invasive, and 95.8%, 35.2%, 76.1%, 50.7%, 67.7% for high-grade muscle-invasive bladder cancer. The specificity was 67.9%, 95.5%, 79.4%, 94.4%, and 83.7%, respectively. The area under the curve (AUC) after receiver operating characteristics (ROC) analysis for high-grade non-muscle-invasive tumors was 0.757, 0.725, 0.819, 0.787, and 0.774, respectively. CONCLUSIONS The analysis of more than 700 urine samples offers an objective view on urine-based rapid diagnostics. Elevated pathological concentrations of markers in urine of bladder cancer patients were detected in all investigated tests. The highest sensitivities for high-grade non-muscle-invasive tumors were calculated for BTA stat® and UBC® Rapid Test, whereas NMP22® BladderChek®, and cytology showed the highest specificities. BTA stat® and UBC® Rapid Test have the potential to be used as a clinical valuable urinary protein biomarker for the detection of high-grade non-muscle-invasive bladder cancer patients and could be included in the management of these tumors.
Collapse
Affiliation(s)
- Thorsten H Ecke
- Department of Urology, Helios Hospital, Bad Saarow, Germany; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
| | - Christina J Meisl
- Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Thorsten Schlomm
- Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Anja Rabien
- Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Flora Labonté
- Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Dezhi Rong
- Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Sebastian Hofbauer
- Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Frank Friedersdorff
- Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany
| | - Lilli Sommerfeldt
- Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany
| | - Nella Gagel
- Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany
| | - Andreas Gössl
- Department of Urology, Rheinland Klinikum Neuss, Neuss, Germany
| | - Dimitri Barski
- Department of Urology, Rheinland Klinikum Neuss, Neuss, Germany
| | - Thomas Otto
- Department of Urology, Rheinland Klinikum Neuss, Neuss, Germany; University Hospital Essen, Essen, Germany
| | - Camilla M Grunewald
- Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Günter Niegisch
- Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | | | - Mario W Kramer
- Department of Urology, University Hospital Lübeck, Lübeck, Germany
| | - Stefan Koch
- Helios Hospital, Institute of Pathology, Bad Saarow, Germany; Brandenburg Medical School, Brandenburg, Germany
| | - Jenny Roggisch
- Helios Hospital, Institute of Pathology, Bad Saarow, Germany
| | | | - Sarah Weiß
- Department of Urology, Helios Hospital, Bad Saarow, Germany
| | - Michael Waldner
- Department of Urology, St. Elisabeth Hospital, Cologne, Germany
| | - Johannes Graff
- Department of Urology, St. Elisabeth Hospital, Cologne, Germany
| | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | | | - Roland Hake
- Institute of Pathology, St. Elisabeth Hospital, Cologne, Germany
| | - Sebastian Eidt
- Institute of Pathology, St. Elisabeth Hospital, Cologne, Germany
| | - Ralph M Wirtz
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| |
Collapse
|
2
|
Wirtz RM, Voss PC, Friedersdorff F, Barski D, Otto T, Waldner M, Veltrup E, Linden F, Schwandt M, Hake R, Eidt S, Roggisch J, Rieger C, Kastner L, Heidenreich A, Koch S, Baum RP, Ecke TH. Prediction of response to neoadjuvant chemotherapy of patients with muscle invasive bladder cancer by molecular subtyping and radioligand target quantitation: Preview of the Bladder BRIDGister. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
Abstract
543 Background: Patients with muscle invasive urothelial carcinoma achieving pathological complete response (pCR) upon neoadjuvant chemotherapy (NACT) have improved prognosis. Molecular subtypes of bladder cancer differ markedly with regard to sensitivity to cisplatinum based chemotherapy and harbour FGFR treatment targets to various content. Previously we did show that lumina tumors respond better to NACT, while FGFR1 expression is associated with chemo resistance (Ecke et al. 2022). The objective of this study was to determine wether radioligand therapy may be an appropriate option in chemoresistent tumors to justify subsequent prospective validation within the "Bladder BRIDGister". Methods: Formalin fixed paraffin embedded (FFPE) tissues from transurethral resections (TUR) before chemotherapy and cystectomy samples after NACT of 36 patients were retrospectively collected. RNA from FFPE tissues were extracted by commercial kits, relative gene expression of subtyping markers (KRT5, KRT20, FGFR1) and radioligand target genes (CXCR4, FAP) were analyzed by standardized RT-qPCR systems (STRATIFYER Molecular Pathology GmbH, Cologne). Spearman correlation, hierarchical clustering, Kruskal-Wallis, chi square and contingency tests were done by JMP 9.0.0 (SAS software). Results: The neoadjuvant cohort consisted of 36 patients (median age: 69, male 83% vs. female 17%) with 92% of patients being histopathologically node negative. When comparing pretreatment with post treatment samples the median expression of KRT20 dropped 128fold, while FGFR1, CXCR4 and FAP mRNA expression increased 6,8fold, 1,9 fold and 2,9 fold, respectively. FAP was positively associated with KRT5, FGFR1 and CXCR4 in treatment naïve TUR biopsies (r=0.4051 p=0.0141, r=0.6458 p<0.0001 and r=0.7586 p<0.0001, respectively), but negatively associated with KRT20 (r=-0.3879 p=0.0194). As previously described, FGFR1 was negatively associated with pCR (r=-0.6418 p<0.0001). Similarly, CXCR4 and FAP trended to be negatively associated with pCR (r=-0.3181 p=0.0586; r=-0.3072 p=0.0684). Hierarchical clustering revealed that CXCR4 and FAP are elevated in stromal rich, KRT5 & KRT20 negative tumors not responding to NACT. Elevated FAP above median mRNA expression was significantly associated with resistance to NACT (chi2 4.314 p=0,0378). Combining elevated FAP and CXCR4 mRNA expression did identify 28% of the patients to be at high risk of NACT resistance (90%). Conclusions: Expression of the radioligand targets CXCR4 and FAP are associated with basal/stromal enriched tumors and resistance to NACT. Theranostic targeting of CXCR4 and FAP before NACT might increase response towards NACT in this poor prognosis group.
Collapse
Affiliation(s)
| | | | - Frank Friedersdorff
- Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | | | - Thomas Otto
- Dpt. of Urology, Rheinlandklinikum, Neuss, Germany
| | | | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | | | | | - Roland Hake
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Sebastian Eidt
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | | | | | - Lucas Kastner
- Department of Urology, University Clinic Cologne, Cologne, Germany
| | - Axel Heidenreich
- Department of Urology, University Hospital of Cologne, Cologne, Germany
| | - Stefan Koch
- Dpt of Pathology, Helios Hospital, Bad Saarow, Germany
| | | | | |
Collapse
|
3
|
Wirtz RM, Voss PC, Friedersdorff F, Barski D, Otto T, Waldner M, Veltrup E, Linden F, Schwandt M, Hake R, Eidt S, Roggisch J, Rieger C, Kastner L, Heidenreich A, Koch S, Ecke TH. Prediction of response to neoadjuvant chemotherapy of patients with muscle invasive bladder cancer by molecular subtyping and antibody drug conjugate target gene quantitation: Preview of Bladder BRIDGister. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
Abstract
545 Background: Patients with muscle invasive urothelial carcinoma achieving pathological complete response (pCR) upon neoadjuvant chemotherapy (NACT) have improved prognosis. Molecular subtypes of bladder cancer differ markedly with regard to sensitivity to cisplatinum based chemotherapy. Previously we did show that luminal tumors respond better to NACT, while FGFR1 expression is associated with chemo resistance (Ecke et al. 2022). The objective of this study was to determine which patients may benefit from Antibody Drug Conjugate (ADC) treatment in addition to NACT to justify subsequent prospective analysis within the "Bladder BRIDGister". Methods: Formalin fixed paraffin embedded (FFPE) tissues from transurethral resections (TUR) before chemotherapy and cystectomy samples after NACT of 36 patients were retrospectively collected. RNA from FFPE tissues were extracted by commercial kits, relative gene expression of subtyping markers (KRT5, KRT20, FGFR1) and radioligand target genes (NECTIN4, TROP2) were analyzed by standardized RT-qPCR systems (STRATIFYER Molecular Pathology GmbH, Cologne). Spearman correlation, hierarchical clustering, Kruskal-Wallis, chi square and contingency tests were done by JMP 9.0.0 (SAS software). Results: The neoadjuvant cohort consisted of 36 patients (median age: 69, male 83% vs. female 17%) with 92% of patients being pathohistologically node negative. When comparing pretreatment with post treatment samples the median expression of KRT20 dropped 128fold, while FGFR1 expression increased 6.8 fold. Interestingly, TROP2 and NECTIN4 mRNA expression also dropped significantly upon NACT by 5.7 fold and 7.1 fold, respectively. TROP2 and NECTIN4 were positively associated with the response marker KRT20 in therapy naïve TUR biopsies (r=0.5562 p=0.0004; r=0.5833 p=0.0002), but negatively associated with the resistance marker FGFR1 (r=-0.2903 p=0,0858; r=-0.3396 p=0,0427). However, TROP2 and NECTIN4 were not associated with pCR in spearman analysis with minor trend for TROP2 (r=0,2139 p=0,2103). Cluster analysis revealed a subgroup of KRT20 positive and FGFR1 negative tumors expression TROP2 and NECTIN4, which achieved 80% pCR. In addition elevated TROP2 and NECTIN4 expression was found in KRT20 positive tumors coexpressing FGFR1 and being resistant to NACT. Conclusions: Expression of the ADC targets TROP2 and NECTIN4 is associated with KRT20 positive, luminal tumors being highly sensitive to neoadjuvant chemotherapy alone. KRT5 positive, basal tumors do exhibit only very low expression of TROP2 and NECTIN4 mRNA. In view of toxicities the addition of TROP2 and NECTIN4 treatment to NACT might be considered only in luminal tumors exhibiting elevated FGFR1 expression as resistance mechanism and therefore do not respond to NACT.
Collapse
Affiliation(s)
| | | | | | | | - Thomas Otto
- Dpt. of Urology, Rheinlandklinikum, Neuss, Germany
| | | | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | | | | | - Roland Hake
- Institute of Pathology, St. Elisabeth-Krankenhaus Hohenlind, Cologne, Germany
| | - Sebastian Eidt
- Institute of Pathology, St. Elisabeth Hospital Hohenlind, Cologne, Germany
| | | | | | - Lucas Kastner
- Department of Urology, University Clinic Cologne, Cologne, Germany
| | | | - Stefan Koch
- Dpt of Pathology, Helios Hospital, Bad Saarow, Germany
| | | |
Collapse
|
4
|
Ecke TH, Voß PC, Schlomm T, Rabien A, Friedersdorff F, Barski D, Otto T, Waldner M, Veltrup E, Linden F, Hake R, Eidt S, Roggisch J, Heidenreich A, Rieger C, Kastner L, Hallmann S, Koch S, Wirtz RM. Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment. Int J Mol Sci 2022; 23:ijms23147898. [PMID: 35887247 PMCID: PMC9323197 DOI: 10.3390/ijms23147898] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 07/08/2022] [Accepted: 07/13/2022] [Indexed: 02/01/2023] Open
Abstract
Patients with muscle-invasive urothelial carcinoma achieving pathological complete response (pCR) upon neoadjuvant chemotherapy (NAC) have improved prognosis. Molecular subtypes of bladder cancer differ markedly regarding sensitivity to cisplatin-based chemotherapy and harbor FGFR treatment targets to various content. The objective of the present study was to evaluate whether preoperative assessment of molecular subtype as well as FGFR target gene expression is predictive for therapeutic outcome—rate of ypT0 status—to justify subsequent prospective validation within the “BladderBRIDGister”. Formalin-fixed paraffin-embedded (FFPE) tissue specimens from transurethral bladder tumor resections (TUR) prior to neoadjuvant chemotherapy and corresponding radical cystectomy samples after chemotherapy of 36 patients were retrospectively collected. RNA from FFPE tissues were extracted by commercial kits, Relative gene expression of subtyping markers (e.g., KRT5, KRT20) and target genes (FGFR1, FGFR3) was analyzed by standardized RT-qPCR systems (STRATIFYER Molecular Pathology GmbH, Cologne). Spearman correlation, Kruskal−Wallis, Mann−Whitney and sensitivity/specificity tests were performed by JMP 9.0.0 (SAS software). The neoadjuvant cohort consisted of 36 patients (median age: 69, male 83% vs. female 17%) with 92% of patients being node-negative during radical cystectomy after 1 to 4 cycles of NAC. When comparing pretreatment with post-treatment samples, the median expression of KRT20 dropped most significantly from DCT 37.38 to 30.65, which compares with a 128-fold decrease. The reduction in gene expression was modest for other luminal marker genes (GATA3 6.8-fold, ERBB2 6.3-fold). In contrast, FGFR1 mRNA expression increased from 33.28 to 35.88 (~6.8-fold increase). Spearman correlation revealed positive association of pretreatment KRT20 mRNA levels with achieving pCR (r = 0.3072: p = 0.0684), whereas pretreatment FGFR1 mRNA was associated with resistance to chemotherapy (r = −0.6418: p < 0.0001). Hierarchical clustering identified luminal tumors of high KRT20 mRNA expression being associated with high pCR rate (10/16; 63%), while the double-negative subgroup with high FGFR1 expression did not respond with pCR (0/9; 0%). Molecular subtyping distinguishes patients with high probability of response from tumors as resistant to neoadjuvant chemotherapy. Targeting FGFR1 in less-differentiated bladder cancer subgroups may sensitize tumors for adopted treatments or subsequent chemotherapy.
Collapse
Affiliation(s)
- Thorsten H. Ecke
- Department of Urology, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany;
- Department of Urology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (P.C.V.); (T.S.); (A.R.); (F.F.)
- Correspondence:
| | - Paula Carolin Voß
- Department of Urology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (P.C.V.); (T.S.); (A.R.); (F.F.)
| | - Thorsten Schlomm
- Department of Urology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (P.C.V.); (T.S.); (A.R.); (F.F.)
| | - Anja Rabien
- Department of Urology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (P.C.V.); (T.S.); (A.R.); (F.F.)
| | - Frank Friedersdorff
- Department of Urology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (P.C.V.); (T.S.); (A.R.); (F.F.)
- Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, 10365 Berlin, Germany
| | - Dimitri Barski
- Department of Urology, Rheinlandklinikum, 41464 Neuss, Germany; (D.B.); (T.O.)
| | - Thomas Otto
- Department of Urology, Rheinlandklinikum, 41464 Neuss, Germany; (D.B.); (T.O.)
| | - Michael Waldner
- Department of Urology, St. Elisabeth Hospital, 50935 Cologne, Germany;
| | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany; (E.V.); (F.L.); (R.M.W.)
| | - Friederike Linden
- STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany; (E.V.); (F.L.); (R.M.W.)
| | - Roland Hake
- Institute of Pathology, St. Elisabeth Hospital, 50935 Cologne, Germany; (R.H.); (S.E.)
| | - Sebastian Eidt
- Institute of Pathology, St. Elisabeth Hospital, 50935 Cologne, Germany; (R.H.); (S.E.)
| | - Jenny Roggisch
- Institute of Pathology, Helios Hospital, 15526 Bad Saarow, Germany; (J.R.); (S.K.)
| | - Axel Heidenreich
- Department of Urology, Universitäsklinikum Köln, 50937 Cologne, Germany; (A.H.); (C.R.); (L.K.)
| | - Constantin Rieger
- Department of Urology, Universitäsklinikum Köln, 50937 Cologne, Germany; (A.H.); (C.R.); (L.K.)
| | - Lucas Kastner
- Department of Urology, Universitäsklinikum Köln, 50937 Cologne, Germany; (A.H.); (C.R.); (L.K.)
| | - Steffen Hallmann
- Department of Urology, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany;
| | - Stefan Koch
- Institute of Pathology, Helios Hospital, 15526 Bad Saarow, Germany; (J.R.); (S.K.)
- Brandenburg Medical School, 16816 Neuruppin, Germany
| | - Ralph M. Wirtz
- STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany; (E.V.); (F.L.); (R.M.W.)
| |
Collapse
|
5
|
Ecke T, Friedersdorff F, Veltrup E, Kilic E, Hake R, Eidt S, Roggisch J, Koch S, Wirtz RM. Association of leucocyte levels in urine with tissue PD-L1 status and immune infiltration into basal bladder cancer subtype in the prospective real-world clinicopathological register trial Bladder BRIDGister. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
560 Background: The objective of the present study was to evaluate whether preoperative standard urine parameters such as leucocyte count in urine samples dominate in particular molecular subtypes of bladder cancer and reflect the immune infiltration status in the tissue in matched urine and TUR biopsy samples from patients being suspicious of bladder cancer and undergoing first TURB within the prospective Real World Experience registry trial "BRIDGister". Methods: For this pilot study paraffin fixed pretreatment tissue samples from the first TURB of 48 pts participating in the BRIDGister trial and matched urine samples were prospectively collected and analyzed. RNA from FFPE tissues were extracted by commercial kits- Relative gene expression of subtyping markers (KRT5, KRT20) by standardized RT-qPCR systems for PD-1, PD-L1, CTLA4 (STRATIFYER Molecular Pathology GmbH, Cologne). In addition urine samples were analyzed for leucocyte and erythrocyte count. Spearman correlation, Kruskal-Wallis, MannWhitney and Sensitivity/Specificity tests were done by JMP 9.0.0 (SAS software). Results: The pilot cohort of the BRIDGister trial consisted of 48 patients (median age: 77, male 65% vs. female 35%) of diverse clinical stages (Benign lesions/no tumor 38%, pTa 23%, pT1 20%, pT2 19%) and WHO 1973 grade (G1 11%, G2 43%, G3 23%). Presence of leucocytes but not erythrocytes was negatively associated with KRT20 (r=-0.4249, p=0.0216) but positive with KRT5 (r=0.3704, p=0.0479). Moreover high levels of leucocytes in urine were positively associated with tumor expression of PD-L1 (r=0.5081, p=0.0041), PD-1 (r=0.5342, p=0.00024) and CTLA4 (r=0.4244, p=0.0194). In contrast there was no significant association of tumor PDL-1, PD-1 and CTLA4 expression with erythrocyte count in urine. Conclusions: Presence of leucotytes in urine is strongly associated with basal subtype and immune cell infiltration into early bladder cancer. As the presence of erythrcytes did not reveal these significant associations, the presence of leucocytes is not due to simple bleeding or tissue vulnerability. Moreover, the strong tumor subtype specificity further demonstrate the basal tumor specificity of urine leucocytes and therefore may be helpful for detecting and monitoring basal bladder cancer in a non invasive fashion. Given the prognostic value of tissue determination of PD-L1, PD-1 and CTLA4 quantitation on mRNA level, these results warrant further investigation to conclude on its impact on outcome prediction (BCG responsiveness, recurrence, progression, etc.), which will be prospectively analyzed in the framework of the ongoing multicenter BRIDGister Real World Experience trial.
Collapse
Affiliation(s)
| | - Frank Friedersdorff
- Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Ergin Kilic
- Institute of Pathology, Klinikum Leverkusen, Leverkusen, Germany
| | - Roland Hake
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Sebastian Eidt
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | | | | | | |
Collapse
|
6
|
Wirtz RM, Watts R, Kellner R, Ortmann R, Horns T, Enderle D, Meyer L, Noerholm M, Morken M, Veltrup E, Hake R, Eidt S, Roggisch J, Koch S, Ecke T. FGFR testing and urine-based risk straticfication from matched tissue and urine samples within the prospective real-world clinicopathological register trial: BRIDGister. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
469 Background: The objective of the present study was to assess FGFR mutattions and fusions from matched urine and tissue samples from patients suspicious of bladder cancer and undergoing first TURB within BRIDGister RealWorld Experience trial. Methods: FFPE samples from the first TURB of 39 pts participating in the BRIDGister trial and matched urine samples were prospectively collected and analyzed. RNA from FFPE tissues were extracted by commercial kits and analyzed by Therascreen FGFR IVD kit (Qiagen GmbH, Hilden). In addition extracellular vesicles were centrally isolated for subsequent RNA extraction (exoRNA.Exosome Diagnostics GmbH, Martinsried) and centrall analysis by QIAcuity digital PCR (Qiagen, Hilden). In addition mRNA based profiling of urine was done by dPCR. Concordance, Spearman, Kruskal-Wallis and MannWhitney were analyzed by JMP 9.0.0 (SAS software). Results: The pilot cohort of the BRIDGister trial consisted of 39 patients (median age: 75, male 69% vs female 31%) of diverse clinical stages (Benign lesions/no tumor 23%, pTa 31%, pT1 26%, pT2 21%) and WHO 1973 grade (G1 8%, G2 39%, G3 34%). Based on FFPE tissue testing using Therascreen FGFR IVD kit and exosomal RNA extraction follwoed by dPCR 12 out of 39 patients exhibited FGFR alterations (31%). Comparison with tissue testing as probable gold standard revealed 67% sensitivity, 85% specificity, 67% PPV and 85%NPV. There were 4 patients being FGFR positive for exoRNA from urine with no mutation found in the corresponding TUR biopsy. Determining ERBB2 mRNA by dPCR from urine revealed that high ERBB2 mRNA correlated with higher WHO1973grade, while high FGFR3 mRNA correlated with lower grade tumors (Spearman r=0.4386 p=0.0075 and r=-0.4663 p=0.0042). Similiarly, trends were seen for association of ERBB2 and FGFR3 mRNA with clinical stage tumors in this pilote cohort (Spearman r=0.2359 p=0.0923 and r=-0.2249 p=0.1089). Conclusions: Extraction of exosomal RNA from urine followed by highly sensitive dPCR mutation testing is feasible with good concordance to matched tissue testing. Urine testing might evolve as alternative approach for FGFR3 screening in a non invasive fashion without the need of transurethral biopsy. Interestingly, mRNA assessment of exosomal RNA from urine before TURB correlated with clinical parameters such as WHO Grade 1973 with ERBB2 mRNA being associated with high grade tumors and FGFR3 mRNA being associated with low grade tumors, which is in line with previous tissue tsting results. This indicates the potential to clinically characterize tumor grade and stage before TUR biopsy or surgery which might be helpful for future risk stratification and planning of surgical intervention. Further exploration is warranted and includes the potential of monitoring patients with regard to urine based mutation detection and risk stratification.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Lisa Meyer
- Exosome Diagnostics GmbH, Martinsried, Germany
| | | | | | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Roland Hake
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Sebastian Eidt
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | | | | | | |
Collapse
|
7
|
Wirtz RM, Veltrup E, Prazeres H, Dias C, Hake R, Eidt S, Vinagre J, Roggisch J, Koch S, Ecke T. Prospective validation of urine based FGFR screening by Uromonitor within the real-world clinicopathological register trial BRIDGister. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
471 Background: The objective of the present study was to prospectively evaluate FGFR mutation detetion in matched urine and tissue samples from patients suspicious of bladder cancer and undergoing first TURB within the framework of the BRIDGister RealWorld Experience trial. Methods: For this pilot study paraffin fixed pretreatment tissue samples from the first TURB of 48 pts participating in the BRIDGister trial and matched urine samples were prospectively collected and analyzed. RNA from FFPE tissues were extracted by commercial kits and analyzed by Therascreen FGFR IVD kit (Qiagen GmbH, Hilden). In addition urine samples were filtered at local urology and filters were shipped for central extraction of cellular DNA (Uromonitor, Porto). Concordance, Kruskal-Wallis, MannWhitney and Sensitivity/Specificity tests were analyzed by JMP 9.0.0 (SAS software). Results: The pilote cohort of the BRIDGister trial consisted of 47 patients (median age: 77, male 65% vs female 35%) of diverse clinical stages (benign lesions/no tumor 38%, pTa 23%, pT1 20%, pT2 19%) and WHO 1973 grade (G1 11%, G2 43%, G3 23%). Based on FFPE tissue testing using Therascreen FGFR IVD kit 10 out of 47 patients exhibited FGFR alterations (25%), while urine filtering for cellular components and subsequent PCR testing revealed 13 out of 40 matched urine sampels were FGFR positive (33%). Comparison with tissue testing as probable gold standard revealed 100% sensitivity, 90% specificity, 77% PPV, 100% NPV as well as high concordance (kappa 0,82, p < 0,0001). There were 3 patients being FGFR positive for Uromonitor from urine with no mutation found in the corresponding TUR biopsy. Conclusions: Filtering urine for cells and subsequent DNA extraction followed by PCR detection results in highly sensitive mutation testing being feasible with good concordance to matched tissue testing. Prospective testing validated the diagnostic accuracy of the Uromonitor FGFR test in a real world setting.
Collapse
Affiliation(s)
| | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | | | | | - Roland Hake
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Sebastian Eidt
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Joao Vinagre
- Universidade do Porto Faculdade de Medicina, I3s, Porto, Portugal
| | | | | | | |
Collapse
|
8
|
Wirtz R, Friedersdorff F, Barski D, Otto T, Bug R, Veltrup E, Kilic E, Hake R, Eidt S, Waldner M, Grabowski P, Pavel M, Roggisch J, Koch S, Heidenreich A, Baum R, Ecke T. Subtype specific expression of radioligand targets in the prospective Real World clinico-pathological register trial BRIDGister. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00172-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
9
|
Wirtz R, Friedersdorff F, Veltrup E, Barski D, Bug R, Otto T, Kilic E, Hake R, Eidt S, Roggisch J, Koch S, Ecke T. Association of Leucocyte levels in urine with tissue PD-L1 status and immune infiltration into basal bladder cancer subtype in the prospective Real World clinicopathological register trial BRIDGister. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00163-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Brueckl NF, Wirtz RM, Reich FPM, Veltrup E, Zeitler G, Meyer C, Wuerflein D, Ficker JH, Eidt S, Brueckl WM. Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2022; 10:4106-4119. [PMID: 35004242 PMCID: PMC8674604 DOI: 10.21037/tlcr-21-587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 10/19/2021] [Indexed: 11/16/2022]
Abstract
Background The aim of this study was to determine whether mRNA expressions and dynamic changes of immune-related genes before and after starting first-line treatment with the PD-1 inhibitor pembrolizumab in patients with NSCLC were of predictive value. Methods CD3, CD8, PD-1, PD-L1 and CTLA-4 mRNA expression levels were measured from peripheral blood before and after three weeks of treatment with the PD-1 inhibitor. Univariate and multivariate analyses were performed retrospectively. Response, progression-free survival (PFS) and overall survival (OS) were determined. Results In univariate analysis an increase of CD3 and CD8 mRNA expression after the first cycle of pembrolizumab were each associated with improved PFS and OS. In contrast, patients with no change or with a decrease in CD3 and CD8 mRNA expression showed significantly worse outcome. CD8 mRNA increase remained an independent predictive factor for PFS and OS in the multivariate analysis with p values of 0.011 and 0.006, respectively. Conclusions An increase of CD8 mRNA expression predicts favorable outcome after first line monotherapy with pembrolizumab, while no change or decrease might serve as an indicator of poor outcome and might give cause for early treatment escalation for instance by addition of chemotherapy or additional ICI treatment, e.g., against CTLA-4.
Collapse
Affiliation(s)
- Natalie F Brueckl
- Department of Pathology, St.-Elisabeth Hospital Cologne, Teaching Hospital of the University of Cologne, Cologne, Germany
| | - Ralph M Wirtz
- Department of Pathology, St.-Elisabeth Hospital Cologne, Teaching Hospital of the University of Cologne, Cologne, Germany.,STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Fabian P M Reich
- Paracelsus Medical University Nuremberg, Nuremberg, Germany.,Department of Respiratory Medicine, Allergology and Sleep Medicine/Nuernberg Lung Cancer Center, Nuernberg General Hospital, Nuremberg, Germany
| | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Gloria Zeitler
- Paracelsus Medical University Nuremberg, Nuremberg, Germany
| | - Christian Meyer
- Paracelsus Medical University Nuremberg, Nuremberg, Germany.,Department of Pathology, Nuremberg General Hospital, Nuremberg, Germany
| | - Dieter Wuerflein
- Paracelsus Medical University Nuremberg, Nuremberg, Germany.,Department of Respiratory Medicine, Allergology and Sleep Medicine/Nuernberg Lung Cancer Center, Nuernberg General Hospital, Nuremberg, Germany
| | - Joachim H Ficker
- Paracelsus Medical University Nuremberg, Nuremberg, Germany.,Department of Respiratory Medicine, Allergology and Sleep Medicine/Nuernberg Lung Cancer Center, Nuernberg General Hospital, Nuremberg, Germany
| | - Sebastian Eidt
- Department of Pathology, St.-Elisabeth Hospital Cologne, Teaching Hospital of the University of Cologne, Cologne, Germany
| | - Wolfgang M Brueckl
- Paracelsus Medical University Nuremberg, Nuremberg, Germany.,Department of Respiratory Medicine, Allergology and Sleep Medicine/Nuernberg Lung Cancer Center, Nuernberg General Hospital, Nuremberg, Germany
| |
Collapse
|
11
|
Wennhold K, Thelen M, Lehmann J, Schran S, Preugszat E, Garcia-Marquez M, Lechner A, Shimabukuro-Vornhagen A, Ercanoglu MS, Klein F, Thangarajah F, Eidt S, Löser H, Bruns C, Quaas A, von Bergwelt-Baildon M, Schlößer HA. CD86 + Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses. Cancer Immunol Res 2021; 9:1098-1108. [PMID: 34155067 DOI: 10.1158/2326-6066.cir-20-0949] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Revised: 02/22/2021] [Accepted: 06/21/2021] [Indexed: 11/16/2022]
Abstract
The role of B cells in antitumor immunity and their impact on emerging immunotherapies is increasingly gaining attention. B-cell effector functions include not only secretion of antibodies, but also presentation of antigens to T cells. A physiologic B-cell subset with immunostimulatory properties was described in humans, defined by a high expression of CD86 and downregulation of CD21. We used multicolor flow cytometry and IHC to elucidate abundance and spatial distribution of these antigen-presenting B cells (BAPC) in blood (peripheral blood mononuclear cells, PBMC) and tumor samples of 237 patients with cancer. Antigen-specific T-cell responses to cancer testis antigens were determined using tetramer staining and sorted BAPCs in FluoroSpot assays for selected patients. We found that BAPCs were increased in the tumor microenvironment of 9 of 10 analyzed cancer types with site-specific variation. BAPCs were not increased in renal cell carcinoma, whereas we found a systemic increase with elevated fractions in tumor-infiltrating lymphocytes (TIL) and PBMCs of patients with colorectal cancer and gastroesophageal adenocarcinoma. BAPCs were localized in lymphoid follicles of tertiary lymphoid structures (TLS) and were enriched in tumors with increased numbers of TLSs. BAPCs isolated from tumor-draining lymph nodes of patients with cancer showed increased percentages of tumor antigen-specific B cells and induced responses of autologous T cells in vitro. Our results highlight the relevance of BAPCs as professional antigen-presenting cells in tumor immunity and provide a mechanistic rationale for the observed correlation of B-cell abundance and response to immune checkpoint inhibition.
Collapse
Affiliation(s)
- Kerstin Wennhold
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Martin Thelen
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Jonas Lehmann
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Simon Schran
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Ella Preugszat
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Maria Garcia-Marquez
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Axel Lechner
- Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical Center, Ludwig Maximilians University, Munich, Germany.,Gene Center, Ludwig Maximilians University, Munich, Germany
| | - Alexander Shimabukuro-Vornhagen
- Department I for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Meryem S Ercanoglu
- Institute of Virology, Laboratory of Experimental Immunology, University of Cologne, Cologne, Germany
| | - Florian Klein
- Institute of Virology, Laboratory of Experimental Immunology, University of Cologne, Cologne, Germany
| | - Fabinshy Thangarajah
- Department of Gynecology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Sebastian Eidt
- Institute of Pathology, St. Elisabeth Hospital, Cologne, Germany
| | - Heike Löser
- Institute of Pathology, University of Cologne, Cologne, Germany
| | - Christiane Bruns
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - Alexander Quaas
- Institute of Pathology, University of Cologne, Cologne, Germany
| | - Michael von Bergwelt-Baildon
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.,Gene Center, Ludwig Maximilians University, Munich, Germany.,Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Hans A Schlößer
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. .,Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| |
Collapse
|
12
|
Wirtz RM, Friedersdorff F, Veltrup E, Kilic E, Watts R, Kellner R, Hake R, Eidt S, Roggisch J, Koch S, Ecke T. Association of FGFR alterations with FGFR 1-4 gene expression in TUR biopsies and matched NMP22 urine levels in early bladder cancer of the prospective real world clinico-pathological register trial: BRIDGister. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e16533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16533 Background: The objective of the present study was to identify molecular charactersitics associated with FGFR positive tumors in matched urine and TUR biopsy samples from patients being suspicious of bladder cancer and undergoing first TURB at the pilot center of the multicentric BRIDGister Real World Experience trial that are helpful for patient management and prognosis. Methods: For this pilot study paraffin fixed pretreatment tissue samples from the first TURB of 28 pts participating in the BRIDGister trial and matched urine samples were prospectively collected and analyzed. RNA from FFPE tissues were extracted by commercial kits and analyzed by Therascreen FGFR IVD kit (Qiagen GmbH, Hilden). Relative gene expression of subtyping markers (KRT5, KRT0) as well as FGFR1, FGFR2, FGFR3, FGFR4, ERBB2 was centrally tested by standardized test systems (STRATIFYER Molecular Pathology GmbH, Cologne). In addition urine samples were analyzed by commercially available urine tests (UBC Rapid, BTA stat, NMP22). Spearman correlation, Kruskal-Wallis, MannWhitney and Sensitivity/Specificity tests were done by JMP 9.0.0 (SAS software). Results: The pilot cohort of the BRIDGister trial consisted of 28 patients (median age: 73, male 71% vs female 29%) of diverse clinical stages (Benign lesions/no tumor 21%, pTa 32%, pT1 21%, pT2 21%) and WHO 1973 grade (G1 7%, G2 43%, G3 21%). Based on FFPE tissue testing using Therascreen FGFR IVD kit 9 out of 28 patients exhibited FGFR alterations (32%). FGFR positive tumors were associated with high expression of FGFR3 mRNA (r = 5.951, p = 0.0011) but low FGFR1 mRNA as well as FGFR4 mRNA (r = -0.3882, p = 0.0412 and r = -0.6305, p = 0.0004, respectively). Interestingly, FGFR alteration was positively associated with the basal marker KRT5 (r = 0.3929, p = 0.0386), but not with luminal KRT20 mRNA expression (r = -0.0208, p = 0.9179). Moreover FGFR3 altered bladder cancer was associated with elevated NMP22 levels in pretreatment urine (r = 0.3978, p = 0.0361). Conclusions: In early bladder cancer FGFR3 alterations are tightly associated with a characteristic FGFR mRNA signature. Mutation/Fusion of FGFR3 results in high FGFR3 but low FGFR1 and FGFR4 mRNA expression, which might be i.a. relevant for the response to FGFR inhibition and important to predict outcome of FGFR inhibitors. Morever FGFR alteration was associated with elevated NMP22 urine levels, which might be helpful for detecting and monitoring FGFR altered bladder cancer in a non invasive fashion. These results warrant further investigation and its impact on outcome prediction (BCG responsiveness, recurrence, proegression, etc) will be prospectively analyzed in the framework of the ongoing multicenter BRIDGister Real World Experience trial.
Collapse
Affiliation(s)
| | - Frank Friedersdorff
- Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Ergin Kilic
- Institute of Pathology, Klinikum Leverkusen, Leverkusen, Germany
| | | | | | - Roland Hake
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Sebastian Eidt
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | | | | | | |
Collapse
|
13
|
Wirtz RM, Watts R, Kellner R, Ortmann R, Horns T, Enderle D, Meyer L, Noerholm M, Morken M, Veltrup E, Hake R, Eidt S, Roggisch J, Koch S, Ecke T. FGFR testing from matched tissue and urine samples within the prospective real world clinico-pathological register trial BRIDGister. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e16532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16532 Background: The objective of the present study was to assess FGFR mutattions and fusions from matched urine and tissue samples from patients suspicious of bladder cancer and undergoing first TURB at the pilot center of the multicentric BRIDGister RealWorld Experience trial Methods: For this pilot study paraffin fixed pretreatment tissue samples from the first TURB of 28 pts participating in the BRIDGister trial and matched urine samples were prospectively collected and analyzed. RNA from FFPE tissues were extracted by commercial kits and analyzed by Therascreen FGFR IVD kit (Qiagen GmbH, Hilden). In addition urine samples were shipped for central isolation of extracellular vesicles and extraction of RNA (exoRNA.Exosome Diagnostics GmbH, Martinsried) and subsequently centrally analyzed by QIAcuity digital PCR (Qiagen, Hilden). Additional urine testing was performed by further technologies including central cytology. Concordance, Kruskal-Wallis, MannWhitney and Sensitivity/Specificity tests were analyzed by JMP 9.0.0 (SAS software). Results: The pilot cohort of the BRIDGister trial consisted of 28 patients (median age: 73, male 71% vs female 29%) of diverse clinical stages (Benign lesions/no tumor 21%, pTa 32%, pT1 21%, pT2 21%) and WHO 1973 grade (G1 7%, G2 43%, G3 21%). Based on FFPE tissue testing using Therascreen FGFR IVD kit 9 out of 28 patients exhibited FGFR alterations (32%). Based on exosomal RNA (exoRNA) and subsequent dPCR testing 8 out of 21 matched urine sampels were FGFR positive (38%). Comparison with tissue testing as probable gold standard revealed 71% sensitivity, 78% specificity, 63% PPV and 85%NPV. There were 3 patients being FGFR positive for exoRNA from urine with no mutation found in the corresponding TUR biopsy. One of these mutations could be validated by independent urine test. Furthermore one tumor harbored two tissue mutations (R248C, Y373C) but three urine mutations (R248C, Y373C, G370C) indicating substantial tumor heterogeneity. One FGFR3-TACC3 fusion was detected from a benign lesion, which was not found by the exosomal urine test. Conclusions: Extraction of exosomal RNA from urine followed by highly sensitive dPCR mutation testing is feasible with good concordance to matched tissue testing. Urine testing bears the potential of detecting additional mutations in a real world setting and might evolve as alternative approach for FGFR3 screening in a non invasive fashion without the need of transurethral biopsy. Discordant cases are further followed up and might reveal validation of mutation status in upcoming recurrences.Further exploration is warranted and includes the potential of monitoring patients with FGFR before and after therapeutic intervention. By the time of the congress an update of the data with approximately 50 matched pairs will be presented.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Lisa Meyer
- Exosome Diagnostics GmbH, Martinsried, Germany
| | | | | | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Roland Hake
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Sebastian Eidt
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | | | | | | |
Collapse
|
14
|
Weiß S, Hallmann S, Koch S, Eidt S, Stoehr R, Veltrup E, Roggisch J, Wirtz RM, Ecke TH. Identifying the Molecular Mechanisms Contributing to Progression, Metastasis, and Death in Low-grade Non-muscle-invasive Bladder Cancer: A Case Report. EUR UROL SUPPL 2021; 27:29-32. [PMID: 34337514 PMCID: PMC8317895 DOI: 10.1016/j.euros.2021.02.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/25/2021] [Indexed: 11/19/2022] Open
Abstract
Transitional cell carcinoma of the bladder is a common malignancy with an estimated 549 393 new cases occurring in 2018 alone. Both non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) show high recurrence and progression rates, and therefore impose a great burden on patients and health care systems. Current risk stratification and therapy strategies are predominantly based on clinical and histopathological findings for tumor stage and grade. The chemoresistance and metastasis of low-grade tumors suggest an incomplete understanding of disease mechanisms, despite numerous studies on differentiating molecular subtypes of bladder cancer to identify tumor drivers and potential therapeutic targets. We present a highly unusual course for a low-grade bladder tumor leading to metastasis and death, for which we used postmortem histopathological and molecular analyses to evaluate targetable alterations in key signaling pathways driving the underlying tumor biology.
Collapse
Affiliation(s)
- Sarah Weiß
- Department of Urology, Helios Hospital, Bad Saarow, Germany
- Corresponding author. Helios Klinikum Bad Saarow, Pieskower Strasse 33, 15526 Bad Saarow, Germany. Tel.: +49 03363173466.
| | | | - Stefan Koch
- Department of Pathology, Helios Hospital, Bad Saarow, Germany
- Brandenburg Medical School, Bad Saarow, Germany
| | - Sebastian Eidt
- Institute of Pathology, St. Elisabeth Hospital Cologne-Hohenlind, Cologne, Germany
| | - Robert Stoehr
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
| | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Jenny Roggisch
- Department of Pathology, Helios Hospital, Bad Saarow, Germany
| | | | | |
Collapse
|
15
|
Breyer J, Monga M, Mayr R, Otto W, Burger M, Eckstein M, Stöhr R, Erben P, Bolenz C, Eidt S, Sundaram R, Baig M, Galluzzi A, Wirtz R, Hartmann A, Santiago-Walker A. 758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
16
|
Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P. mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. Int J Mol Sci 2018; 19:E3396. [PMID: 30380731 PMCID: PMC6274690 DOI: 10.3390/ijms19113396] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2018] [Revised: 10/14/2018] [Accepted: 10/22/2018] [Indexed: 11/16/2022] Open
Abstract
Recently, muscle-invasive bladder cancer (MIBC) has been subclassified by gene expression profiling, with a substantial impact on therapy response and patient outcome. We tested whether these complex molecular subtypes of MIBC can be determined by mRNA detection of keratin 5 (KRT5) and keratin 20 (KRT20). Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) was applied to quantify gene expression of KRT5 and KRT20 using TaqMan®-based assays in 122 curatively treated MIBC patients (median age 68.0 years). Furthermore, in silico analysis of the MD Anderson Cancer Center (MDACC) cohort (GSE48277 + GSE47993) was performed. High expression of KRT5 and low expression of KRT20 were associated with significantly improved recurrence-free survival (RFS) and disease-specific survival disease specific survival (DSS: 5-year DSS for KRT5 high: 58%; 5-year DSS for KRT20 high: 29%). KRT5 and KRT20 were associated with rates of lymphovascular invasion and lymphonodal metastasis. The combination of KRT5 and KRT20 allowed identification of patients with a very poor prognosis (KRT20⁺/KRT5-, 5-year DSS 0%, p < 0.0001). In silico analysis of the independent MDACC cohorts revealed congruent results (5-year DSS for KRT20 low vs. high: 84% vs. 40%, p = 0.042). High KRT20-expressing tumors as well as KRT20⁺/KRT- tumors were significantly enriched with aggressive urothelial carcinoma variants (micropapillary, plasmacytoid, nested).
Collapse
Affiliation(s)
- Markus Eckstein
- Institute of Pathology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
| | - Ralph Markus Wirtz
- STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany.
- Institute of Pathology at the St Elisabeth Hospital Köln-Hohenlind, 50935 Cologne, Germany.
| | - Matthias Gross-Weege
- Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
| | - Johannes Breyer
- Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
| | - Wolfgang Otto
- Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
| | - Robert Stoehr
- Institute of Pathology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
| | - Danijel Sikic
- Department of Urology and Pediatric Urology, University Hospital Erlangen, 91058 Erlangen, Germany.
| | - Bastian Keck
- Department of Urology and Pediatric Urology, University Hospital Erlangen, 91058 Erlangen, Germany.
| | - Sebastian Eidt
- Institute of Pathology at the St Elisabeth Hospital Köln-Hohenlind, 50935 Cologne, Germany.
| | - Maximilian Burger
- Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
| | | | - Katja Nitschke
- Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
| | - Stefan Porubsky
- Department of Pathology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
| | - Arndt Hartmann
- Institute of Pathology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
| | - Philipp Erben
- Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
| |
Collapse
|
17
|
Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget 2018; 9:15001-15014. [PMID: 29599921 PMCID: PMC5871092 DOI: 10.18632/oncotarget.24531] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 02/10/2018] [Indexed: 01/05/2023] Open
Abstract
Background Immunohistochemical PD-L1 assessment is currently used to identify responders towards checkpoint inhibitors although it is limited by inter-observer effects. Here, we conducted a multi-center round robin test to prove the possibility of assessing the PD-L1 status by gene expression to avoid inter-observer effects. Patients and methods Gene expression of PD-L1 was analyzed in a total of 294 samples (14 cases non-muscle invasive and muscle-invasive bladder cancer; MIBC) in seven centers by a RT-qPCR kit and compared with immunohistochemical scoring of three pathologists (DAKO, 22c3). Both assays were compared towards prognosis prediction in a cohort of 88 patients with MIBC. Results PD-L1 gene expression revealed very high inter center correlation (centrally extracted RNA: r = 0.68–0.98, p ≤ 0.0076; locally extracted RNA: r = 0.81–0.98, p ≤ 0.0014). IHC Inter-observer concordance was moderate to substantial for immune cells (IC), fair for combined IC/ tumor cell (TC) (IC: κ = 0.50–0.61; IC + TC: κ = 0.50), and fair for TC scoring (κ = 0.26–0.35). Gene expression assessment resulted in more positive cases (9/14 cases positive vs. 6/14 cases [IHC]) which could be validated in the independent cohort. Positive mRNA status was associated with significantly better overall and disease-specific survival (5-year OS: 50% vs. 26%, p = 0.0042, HR = 0.48; 5 year DSS: 65% vs. 40%, p = 0.012, HR = 0.49). The 1% IHC IC cut-off also revealed significant better OS (5 year OS: 58% vs. 31%, p = 0.036, HR = 0.62). Conclusion Gene expression showed very high inter-center agreement. Gene expression assessment also resulted in more positive cases and revealed better prognosis prediction. PD-L1 mRNA expression seems to be a reproducible and robust tool for PD-L1 assessment.
Collapse
Affiliation(s)
- Markus Eckstein
- Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Ralph M Wirtz
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany.,Institute of Pathology at The St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Carolin Pfannstil
- Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Sven Wach
- Department of Urology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Robert Stoehr
- Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Johannes Breyer
- Department of Urology, University of Regensburg, Regensburg, Germany
| | | | - Cagatay Günes
- Department of Urology, University of Ulm, Ulm, Germany
| | - Katja Nitschke
- Department of Urology Mannheim, University of Heidelberg, Mannheim, Germany
| | - Wilko Weichert
- Institute of Pathology, Technical University Munich, Munich, Germany
| | - Wolfgang Otto
- Department of Urology, University of Regensburg, Regensburg, Germany
| | - Bastian Keck
- Department of Urology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Sebastian Eidt
- Institute of Pathology at The St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Maximilian Burger
- Department of Urology, University of Regensburg, Regensburg, Germany
| | - Helge Taubert
- Department of Urology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Bernd Wullich
- Department of Urology, University of Erlangen-Nuremberg, Erlangen, Germany
| | | | - Arndt Hartmann
- Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Philipp Erben
- Department of Urology Mannheim, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
18
|
Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget 2017; 8:67684-67695. [PMID: 28978063 PMCID: PMC5620203 DOI: 10.18632/oncotarget.18804] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Accepted: 06/02/2017] [Indexed: 12/21/2022] Open
Abstract
Expression of ESR1, PGR, HER2 and Ki67 is important for risk stratification and therapy in breast cancer. Hormone receptor expression can also be found in MIBC, reflecting luminal and basal subtypes of breast cancer. Thus the purpose was to investigate on the mRNA expression of the aforementioned markers and their prognostic value in pT1 bladder cancer. Retrospective analysis of clinical data and Formalin-Fixed Paraffin-Embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder was performed. mRNA expression was measured by single step RT-qPCR. Relative gene expression was determined by normalization to two housekeeping genes (CALM2, B2M) using the 40-ΔΔCT method. Correlation of mRNA expression with outcome was assessed using Kaplan-Meier analysis and multivariate Cox regression analysis. From overall 302 patients, 255 samples could be analyzed with valid measurements. Subtype distribution was Luminal-A in 11.4%, Luminal-B in 38.8%, triple negative in 36.9% and ERBB2 in 12.9%, respectively. Kaplan-Meier analysis revealed molecular subtyping being statistical significant for RFS (p=0.0408) and PFS (p=0.0039). Luminal-A patients did have the best RFS and PFS. Multivariate analysis revealed molecular subtyping to be significant for PFS (L-R Chi2 of 11.89, p=0.0078). Elevated expression of HER2 was statistically significant for PFS (p=0.0025) and discriminated among G3 tumors a high risk group (60% PFS) from a low risk risk group (90% PFS) after 5 year follow-up (p<0.001). Expression of ESR1, PGR and HER2 has predictive value in stage pT1 NMIBC and reveals potential therapeutic targets.
Collapse
Affiliation(s)
- Johannes Breyer
- Department of Urology, University of Regensburg, Regensburg, Germany
| | - Ralph Markus Wirtz
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany.,Institute of Pathology at The St Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Wolfgang Otto
- Department of Urology, University of Regensburg, Regensburg, Germany
| | | | | | - Philipp Erben
- Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Maximilian Christian Kriegmair
- Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Robert Stoehr
- Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Sebastian Eidt
- Institute of Pathology at The St Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Stefan Denzinger
- Department of Urology, University of Regensburg, Regensburg, Germany
| | - Maximilian Burger
- Department of Urology, University of Regensburg, Regensburg, Germany
| | - Arndt Hartmann
- Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
| |
Collapse
|
19
|
Wirtz RM, Scheffen I, Marme F, Laible M, Sclombs K, Schumacher C, Schneeweiss A, Eidt S, Sinn HP. Abstract P2-05-25: Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Quantitative determination of estrogen receptor mRNA expression in luminal breast tumors is predictive for benefit from adjuvant tamoxifen compared to placebo treatment as has been shown in the large randomized NSABP B-14 trial, while protein determination by IHC or LBA is not (Kim et al JCO 2011). Interestingly, the ultrahigh expression of ESR1 mRNA (above ER score 10 by Oncotype test) has been indicative for tamoxifen benefit. This predictive cut-off value of mRNA expression is significantly higher than the diagnostic cut-off (at ER score 6.5). Here we tested wether the ultrahigh expression of ESR1 mRNA determined by commercial MammaTyper® testing is predictive for survival after neoadjuvant chemotherapy treatment of advanced breast cancer.
Materials and Methods
Pretreatment core cut biopsies from n=54 patients with PBC treated within a randomized phase II trial (2) of anthracyline/taxane based NAC with available clinical follow-up information were examined. RNA was extracted from the FFPE sections and ESR1 mRNA from each section was measured by commercial assays. For technical comparison of ESR1 mRNA values by Oncotype DX versus MammaTyper® from n=113 surgical samples were analyzed by both commercial assays in a blinded fashion. Statistical analysis was performed using the SAS JMP® 9.0.0 software.
Results
Quantification of ESR1 mRNA expression after RNA extraction from separate slices of 113 primary breast tumors and determination by different commercial RT-qPCR assays resulted in high correlation of continuous expression results (Spearman r=0,85; p<0,0001). The rate of ESR1 mRNA negative cases by both methods by predefined diagnostic cut-offs was low in this cohort (1/113 and 6/113, respectively) resulting in high concordance for positive ER status by both methods.The median expression of ER score and ESR1 40-DDCq was high (10,2 and 39,8, respectively) and almost exactly at the predictive ER score cut-off. Hence, the Tamoxifen benefit cut-off of ER score 10 by Oncotype is comparable with a 40-DDCqvalue of 39,6 for ESR1 mRNA determination by MammaTyper®, which resembles an ESR1 mRNA expression 3fold above the diagnostic cut-off. In the independent chemotherapy cohort theoptimal discrimination for overall survival could be achieved by an elevated ESR1 mRNA expression exactly at 39,6 resulting in 100% overall survival for ultra-high expressors and 75 % overall survival for lower ESR1 mRNA expression after 5 years (p=0,006).
Conclusion
Previous data suggest that ultrahigh expression of ESR1 mRNA is predictive for improved overall survival and tamoxifen benefit (1). Here we show that ultrahigh expression of ESR1 mRNA is also prognostic in more advanced breast tumors after neoadjuvant chemotherapy. These findings validate the importance of quantitative determination of estrogen receptor expression and substantiate the understanding of receptor expression being a continuous determinant with indication specific cut-off values. Ultrahigh expression of ESR1 seems to identify a distinct subset of luminal breast tumors with superior prognosis and benefit from tamoxifen treatment. These findings warrant further investigation, which are currently being done in independent large breast cancer cohorts.
Citation Format: Wirtz RM, Scheffen I, Marme F, Laible M, Sclombs K, Schumacher C, Schneeweiss A, Eidt S, Sinn H-P. Predictive value of ultra-high ESR1 mRNA expression in early breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-25.
Collapse
Affiliation(s)
- RM Wirtz
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| | - I Scheffen
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| | - F Marme
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| | - M Laible
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| | - K Sclombs
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| | - C Schumacher
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| | - A Schneeweiss
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| | - S Eidt
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| | - H-P Sinn
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany; St. Elisabeth-Hospital Köln-Hohenlnd, Cologne, Germany; National Center for Tumor Diseases, University-Hospital Heidelberg, Heidelberg, Germany; BioNTech Diagnostics GmbH, Mainz, Germany; Institute of Pathology at the St. Elisabeth-Hospital Köln-Hohenlind, Cologne, Germany; Unibversity Clinic Heidelberg, Heidelberg, Germany
| |
Collapse
|
20
|
Sinn HP, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, Lakis S, Veltrup E, Altevogt P, Eidt S, Wirtz RM, Marmé F. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer 2017; 17:124. [PMID: 28193205 PMCID: PMC5307758 DOI: 10.1186/s12885-017-3111-1] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Accepted: 02/04/2017] [Indexed: 12/23/2022] Open
Abstract
Background Proliferation may predict response to neoadjuvant therapy of breast cancer and is commonly assessed by manual scoring of slides stained by immunohistochemistry (IHC) for Ki-67 similar to ER and PgR. This method carries significant intra- and inter-observer variability. Automatic scoring of Ki-67 with digital image analysis (qIHC) or assessment of MKI67 gene expression with RT-qPCR may improve diagnostic accuracy. Methods Ki-67 IHC visual assessment was compared to the IHC nuclear tool (AperioTM) on core biopsies from a randomized neoadjuvant clinical trial. Expression of ESR1, PGR and MKI67 by RT-qPCR was performed on RNA extracted from the same formalin-fixed paraffin-embedded tissue. Concordance between the three methods (vIHC, qIHC and RT-qPCR) was assessed for all 3 markers. The potential of Ki-67 IHC and RT-qPCR to predict pathological complete response (pCR) was evaluated using ROC analysis and non-parametric Mann-Whitney Test. Results Correlation between methods (qIHC versus RT-qPCR) was high for ER and PgR (spearman´s r = 0.82, p < 0.0001 and r = 0.86, p < 0.0001, respectively) resulting in high levels of concordance using predefined cut-offs. When comparing qIHC of ER and PgR with RT-qPCR of ESR1 and PGR the overall agreement was 96.6 and 91.4%, respectively, while overall agreement of visual IHC with RT-qPCR was slightly lower for ER/ESR1 and PR/PGR (91.2 and 92.9%, respectively). In contrast, only a moderate correlation was observed between qIHC and RT-qPCR continuous data for Ki-67/MKI67 (Spearman’s r = 0.50, p = 0.0001). Up to now no predictive cut-off for Ki-67 assessment by IHC has been established to predict response to neoadjuvant chemotherapy. Setting the desired sensitivity at 100%, specificity for the prediction of pCR (ypT0ypN0) was significantly higher for mRNA than for protein (68.9% vs. 22.2%). Moreover, the proliferation levels in patients achieving a pCR versus not differed significantly using MKI67 RNA expression (Mann-Whitney p = 0.002), but not with qIHC of Ki-67 (Mann-Whitney p = 0.097) or vIHC of Ki-67 (p = 0.131). Conclusion Digital image analysis can successfully be implemented for assessing ER, PR and Ki-67. IHC for ER and PR reveals high concordance with RT-qPCR. However, RT-qPCR displays a broader dynamic range and higher sensitivity than IHC. Moreover, correlation between Ki-67 qIHC and RT-qPCR is only moderate and RT-qPCR with MammaTyper® outperforms qIHC in predicting pCR. Both methods yield improvements to error-prone manual scoring of Ki-67. However, RT-qPCR was significantly more specific. Electronic supplementary material The online version of this article (doi:10.1186/s12885-017-3111-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Hans-Peter Sinn
- Institute of Pathology, University of Heidelberg, Im Neuenheimer Feld 220-221, 69120, Heidelberg, Germany.
| | - Andreas Schneeweiss
- National Center for Tumor Diseases, University-Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany
| | - Marius Keller
- Institute of Pathology, University of Heidelberg, Im Neuenheimer Feld 220-221, 69120, Heidelberg, Germany
| | | | - Mark Laible
- BioNTech Diagnostics GmbH, 55131, Mainz, Germany
| | - Julia Seitz
- National Center for Tumor Diseases, University-Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany
| | - Sotirios Lakis
- STRATIFYER Molecular Pathology GmbH, Werthmannstr. 1c, 50935, Köln, Germany
| | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Werthmannstr. 1c, 50935, Köln, Germany
| | - Peter Altevogt
- German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Sebastian Eidt
- Department of Pathology, St. Elisabeth-Krankenhaus, Werthmannstr. 1c, 50935, Köln, Germany
| | - Ralph M Wirtz
- STRATIFYER Molecular Pathology GmbH, Werthmannstr. 1c, 50935, Köln, Germany.,Department of Pathology, St. Elisabeth-Krankenhaus, Werthmannstr. 1c, 50935, Köln, Germany
| | - Frederik Marmé
- National Center for Tumor Diseases, University-Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany
| |
Collapse
|
21
|
Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A. ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Urol Int 2016; 98:282-289. [DOI: 10.1159/000453670] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2016] [Accepted: 11/21/2016] [Indexed: 11/19/2022]
|
22
|
Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W. ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Arch 2016; 469:547-552. [PMID: 27514658 DOI: 10.1007/s00428-016-2002-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 06/24/2016] [Accepted: 08/03/2016] [Indexed: 12/21/2022]
Abstract
Pathological staging and grading are crucial for risk assessment in non-muscle-invasive bladder cancer (NMIBC). Molecular grading might support pathological evaluation and minimize interobserver variability. In this study, the well-established breast cancer markers ESR1, PGR, ERBB2, and MKI67 were evaluated as potential molecular markers to support grading and staging in NMIBC. We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with NMIBC. Messenger RNA (mRNA) expression of the aforementioned markers was measured by single-step reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) using RNA-specific TaqMan assays. Relative gene expression was determined by normalization to two reference genes (CALM2 and B2M) using the 40-ΔΔCT method and correlated to histopathological stage and grade. Pathological assessment was performed by an experienced uropathologist. Statistical analysis was performed using the SAS software JMP 9.0.0 version and GraphPad Prism 5.04. Of 381 cases of NMIBC, samples of 100 pTa and 255 pT1 cases were included in the final study. Spearman rank correlation revealed significant correlations between grade and expression of MKI67 (r = 0.52, p < 0.0001), ESR1 (r = 0.25, p < 0.0001), and ERBB2 (r = 0.18, p = 0.0008). In Mann-Whitney tests, MKI67 was significantly different between all grades (p < 0.0001), while ESR1 (p = 0.0006) and ERBB2 (p = 0.027) were significantly different between G2 and G3. Higher expression of MKI67 (r = 0.49; p < 0.0001), ERBB2 (r = 0.22; p < 0.0001), and ESR1 (r = 0.18; p = 0.0009) mRNA was positively correlated with higher stage. MKI67 (p < 0.0001), ERBB2 (p = 0.0058), and PGR (p = 0.0007) were significantly different between pTa and pT1. In NMIBC expression of ESR1, ERBB2 and MKI67 are significantly different between stage and grade. This potentially provides objective parameters for pathological evaluation.
Collapse
Affiliation(s)
- Johannes Breyer
- Department of Urology, University of Regensburg, Caritas Krankenhaus St. Josef, Landshuter Str. 65, 93053, Regensburg, Germany.
| | - Ralph M Wirtz
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany.,Institute of Pathology at the St Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | | | | | - Philipp Erben
- Department of Urology, University of Mannheim, Mannheim, Germany
| | | | - Robert Stoehr
- Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Sebastian Eidt
- Institute of Pathology at the St Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Stefan Denzinger
- Department of Urology, University of Regensburg, Caritas Krankenhaus St. Josef, Landshuter Str. 65, 93053, Regensburg, Germany
| | - Maximilian Burger
- Department of Urology, University of Regensburg, Caritas Krankenhaus St. Josef, Landshuter Str. 65, 93053, Regensburg, Germany
| | - Arndt Hartmann
- Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Wolfgang Otto
- Department of Urology, University of Regensburg, Caritas Krankenhaus St. Josef, Landshuter Str. 65, 93053, Regensburg, Germany
| |
Collapse
|
23
|
Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, Stöhr R, Eidt S, Hartmann A, Wirtz RM, Sahin U. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 2016; 16:398. [PMID: 27389414 PMCID: PMC4936300 DOI: 10.1186/s12885-016-2476-x] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Accepted: 06/30/2016] [Indexed: 01/03/2023] Open
Abstract
Background MammaTyper is a novel CE-marked in vitro diagnostic RT-qPCR assay which assigns routinely processed breast cancer specimens into the molecular subtypes Luminal A-like, Luminal B-like (HER2 positive or negative), HER2 positive (non-luminal) and Triple negative (ductal) according to the mRNA expression of ERBB2, ESR1, PGR and MKI67 and the St Gallen consensus surrogate clinical definition. Until now and regarding formalin-fixed, paraffin-embedded material (FFPE), this has been a task mostly accomplished by immunohistochemistry (IHC). However the discrepancy rates of IHC for the four breast cancer biomarkers are frequently under debate, especially for Ki-67 which carries the highest degree of inter- and even intra-observer variability. Herein we describe a series of studies in FFPE specimens which aim to fully validate the analytical performance of the MammaTyper assay, including the site to site reproducibility of the individual marker measurements. Methods Tumor RNA was extracted with the novel RNXtract RNA extraction kit. Synthetic RNA was used to assess the sensitivity of the RNXtract kit. DNA and RNA specific qPCR assays were used so as to determine analyte specificity of RNXtract. For the assessment of limit of blank, limit of detection, analytical measurement range and PCR efficiency of the MammaTyper kit serial dilutions of samples were used. Analytical precision studies of MammaTyper were built around two different real time PCR platforms and involved breast tumor samples belonging to different subtypes analyzed across multiple sites and under various stipulated conditions. The MammaTyper assay robustness was tested against RNA input variations, alternative extraction methods and tumor cell content. Results Individual assays were linear up to at least 32.33 and 33.56 Cqs (quantification cycles) for the two qPCR platforms tested. PCR efficiency ranged from 99 to 109 %. In qPCR platform 1, estimates for assay specific inter-site standard deviations (SD) were between 0.14 and 0.20 Cqs accompanied by >94 % concordant single marker assignments for all four markers. In platform 2, the inter-site SD estimates were between 0.40 and 0.66 Cqs while the concordance for single marker assignments was >94 % for all four markers. The agreement reached between the two qPCR systems located in one site was 100 % for ERBB2, 96.9 % for ESR1, 97.2 % for PGR and 98.6 % for MKI67. RT-qPCR for individual markers was stable up to a 64-fold dilution for a typical clinical sample. There was no change in assay performance detected at the level of individual markers or subtypes after using different RNA isolation methods. The presence of up to 80 % of surrounding non-tumor tissue including in situ carcinoma did not affect the assay output. Sixteen out of 20 RNXtract eluates yielded more than 50 ng/μl of RNA (average RNA output: 233 ng/μl), whereas DNA contamination per sample was restricted to less than 15 ng/μl. Median recovery rate of RNA extraction was 91.0 %. Conclusions In this study the performance characteristics of MammaTyper were successfully validated. The various sources of analytical perturbations resulted in negligible variations in individual marker assessments. Therefore, MammaTyper may serve as a technical improvement to current standards for decentralized FFPE-based routine assessment of the commonly used breast cancer biomarkers and for molecular subtyping of breast cancer specimens. Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2476-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | | | | | - Elke Veltrup
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Stefanie Herlein
- Institute of Pathology, University of Erlangen, Erlangen, Germany
| | - Sotiris Lakis
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Robert Stöhr
- Institute of Pathology, University of Erlangen, Erlangen, Germany
| | - Sebastian Eidt
- Institut für Pathologie am St. Elisabeth-Krankenhaus, Cologne, Germany
| | - Arndt Hartmann
- Institute of Pathology, University of Erlangen, Erlangen, Germany
| | - Ralph M Wirtz
- STRATIFYER Molecular Pathology GmbH, Cologne, Germany
| | - Ugur Sahin
- BioNTech Diagnostics GmbH, Mainz, Germany
| |
Collapse
|
24
|
Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P, Turpeenniemi-Hujanen T, Jyrkkiö S, Lakis S, Schlombs K, Laible M, Weber S, Eidt S, Sahin U, Joensuu H. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Res Treat 2016; 157:437-46. [PMID: 27220750 PMCID: PMC4903103 DOI: 10.1007/s10549-016-3835-7] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Accepted: 05/13/2016] [Indexed: 12/23/2022]
Abstract
The biological subtype of breast cancer influences the selection of systemic therapy. Distinction between luminal A and B cancers depends on consistent assessment of Ki-67, but substantial intra-observer and inter-observer variability exists when immunohistochemistry (IHC) is used. We compared RT-qPCR with IHC in the assessment of Ki-67 and other standard factors used in breast cancer subtyping. RNA was extracted from archival breast tumour tissue of 769 women randomly assigned to the FinHer trial. Cancer ESR1, PGR, ERBB2 and MKI67 mRNA content was quantitated with an RT-qPCR assay. Local pathologists assessed ER, PgR and Ki-67 expression using IHC. HER2 amplification was identified with chromogenic in situ hybridization (CISH) centrally. The results were correlated with distant disease-free survival (DDFS) and overall survival (OS). qPCR-based and IHC-based assessments of ER and PgR showed good concordance. Both low tumour MKI67 mRNA (RT-qPCR) and Ki-67 protein (IHC) levels were prognostic for favourable DDFS [hazard ratio (HR) 0.42, 95 % CI 0.25–0.71, P = 0.001; and HR 0.56, 0.37–0.84, P = 0.005, respectively] and OS. In multivariable analyses, cancer MKI67 mRNA content had independent influence on DDFS (adjusted HR 0.51, 95 % CI 0.29–0.89, P = 0.019) while Ki-67 protein expression had not any influence (P = 0.266) whereas both assessments influenced independently OS. Luminal B patients treated with docetaxel-FEC had more favourable DDFS and OS than those treated with vinorelbine-FEC when the subtype was defined by RT-qPCR (for DDFS, HR 0.52, 95 % CI 0.29–0.94, P = 0.031), but not when defined using IHC. Breast cancer subtypes approximated with RT-qPCR and IHC show good concordance, but cancer MKI67 mRNA content correlated slightly better with DDFS than Ki-67 expression. The findings based on MKI67 mRNA content suggest that patients with luminal B cancer benefit more from docetaxel-FEC than from vinorelbine-FEC.
Collapse
Affiliation(s)
- Ralph M Wirtz
- STRATIFYER Molecular Pathology GmbH, Werthmannstr. 1c, 50935, Cologne, Germany.
| | - Harri Sihto
- Laboratory of Molecular Oncology, Translational Cancer Biology Program, University of Helsinki, Helsinki, Finland
| | - Jorma Isola
- Laboratory of Cancer Biology, Institute of Medical Technology, Tampere, Finland
| | - Päivi Heikkilä
- Department of Pathology, HUSLAB, Helsinki University Hospital and Helsinki University, Helsinki, Finland
| | | | - Päivi Auvinen
- Cancer Center, Kuopio University Hospital, Kuopio, Finland
| | | | - Sirkku Jyrkkiö
- Department of Oncology, Turku University Hospital, Turku, Finland
| | - Sotiris Lakis
- STRATIFYER Molecular Pathology GmbH, Werthmannstr. 1c, 50935, Cologne, Germany
| | | | | | | | - Sebastian Eidt
- Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany
| | - Ugur Sahin
- BioNTech Diagnostics GmbH, Mainz, Germany
| | - Heikki Joensuu
- Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| |
Collapse
|
25
|
Wirtz RM, Scheffen I, Marme F, Laible M, Schlombs K, Hake R, Schumacher C, Schneeweiss A, Eidt S, Sinn HP. Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e12045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Iris Scheffen
- St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | - Frederik Marme
- National Center for Tumor disease/Department of Gynecology, University of Heidelberg, Heidelberg, Germany
| | | | | | - Roland Hake
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | | | | | - Sebastian Eidt
- Department of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany
| | | |
Collapse
|
26
|
Shimabukuro-Vornhagen A, Schlößer HA, Gryschok L, Malcher J, Wennhold K, Garcia-Marquez M, Herbold T, Neuhaus LS, Becker HJ, Fiedler A, Scherwitz P, Koslowsky T, Hake R, Stippel DL, Hölscher AH, Eidt S, Hallek M, Theurich S, von Bergwelt-Baildon MS. Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget 2015; 5:4651-64. [PMID: 25026291 PMCID: PMC4148088 DOI: 10.18632/oncotarget.1701] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Purpose: A precise understanding of the mechanisms by which human immune cell subsets affect tumor biology will be critical for successful treatment of cancer using immunotherapeutic approaches. Recent evidence suggests that B cells can both promote and inhibit the development and progression of tumors. The aim of this study was to characterize the composition of the B-cell infiltrates in colorectal cancers (CRC) in order to gain further insight into the role of B cells in CRC. Experimental Design: In this study we characterized B-cell subsets in primary tumors (n=38), metastases (n=6) and blood (n=46) of 51 patients with a diagnosis of CRC and blood of 10 healthy controls. B-cell subsets were analyzed by flow cytometry or immunohistochemistry. Results: Peripheral blood of CRC patients contained a higher percentage of memory B cells than that of age-matched healthy controls. Furthermore, the percentage of B cells within tumors was higher than that in the peripheral blood of CRC patients while metastases were typically devoid of tumor-infiltrating B cells. Tumor-associated B cells were enriched for activated and terminally differentiated B cells. Relevant proportions of regulatory B cells could only be detected in advanced cancer and metastases. Conclusion: B cells constitute a significant proportion of the immune infiltrate in CRC. The B-cell infiltrate of primary CRC is characterized by an accumulation of terminally differentiated memory B cells or plasma cells suggestive of a specific immune response against the tumor. However advanced tumors and metastases are also infiltrated by a considerable number of regulatory B cells.
Collapse
Affiliation(s)
- Alexander Shimabukuro-Vornhagen
- Cologne Interventional Immunology, University of Cologne, Germany. Department I of Internal Medicine, University of Cologne, Cologne, Germany. This authors contributed equally to this work
| | - Hans A Schlößer
- Cologne Interventional Immunology, University of Cologne, Germany. Department of General, Visceral and Cancer Surgery, University of Cologne, Germany. This authors contributed equally to this work
| | - Luise Gryschok
- Cologne Interventional Immunology, University of Cologne, Germany
| | - Joke Malcher
- Cologne Interventional Immunology, University of Cologne, Germany
| | - Kerstin Wennhold
- Cologne Interventional Immunology, University of Cologne, Germany
| | | | - Till Herbold
- Cologne Interventional Immunology, University of Cologne, Germany. Department of General, Visceral and Cancer Surgery, University of Cologne, Germany
| | - Laura S Neuhaus
- Cologne Interventional Immunology, University of Cologne, Germany
| | - Hans J Becker
- Cologne Interventional Immunology, University of Cologne, Germany
| | - Anne Fiedler
- Cologne Interventional Immunology, University of Cologne, Germany
| | | | | | - Roland Hake
- Institute of Pathology, St. Elisabeth Hospital, Cologne, Germany
| | - Dirk L Stippel
- Department of General, Visceral and Cancer Surgery, University of Cologne, Germany
| | - Arnulf H Hölscher
- Department of General, Visceral and Cancer Surgery, University of Cologne, Germany
| | - Sebastian Eidt
- Institute of Pathology, St. Elisabeth Hospital, Cologne, Germany
| | - Michael Hallek
- Department I of Internal Medicine, University of Cologne, Cologne, Germany
| | - Sebastian Theurich
- Cologne Interventional Immunology, University of Cologne, Germany. Department I of Internal Medicine, University of Cologne, Cologne, Germany
| | - Michael S von Bergwelt-Baildon
- Cologne Interventional Immunology, University of Cologne, Germany. Department I of Internal Medicine, University of Cologne, Cologne, Germany
| |
Collapse
|
27
|
Wirtz RM, Kellokumpu-Lehtinen PL, Isola J, Kataja V, Bono P, Turpeenniemi-Hujanen T, Jyrkkiö S, Sitho H, Eidt S, Sahin U, Joensuu H. Abstract P5-02-01: Comparison of ESR1, PGR, HER2 and KI67 expression by central IHC and MammaTyper® RT-qPCR kit in the FinHer trial. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p5-02-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Subtyping of breast cancer has become an integral part of standard evaluation of breast cancer patients1. However, assaying of ER, PgR and Her-2/neu by immunohistochemistry (IHC) carries an up to 20% risk of erroneous results2,3. Moreover, reliable assessment of Ki-67 by IHC in grade 2 breast cancer is challenging due to high intra- and interobserver variations4,5. Interobserver concordance for ESR1, PGR, HER2, and KI67 determination on mRNA level using MammaTyper® reagents were 96.8%, 97.2%, 100%, 97.6%, respectively, based on predefined cutoffs (Laible et al., abstract submitted). Here we tested the clinical concordance and prognostic value of MammaTyper® determinations in the FinHer trial patient population.
Methods: RNA was extracted from formalin-fixed paraffin-embedded (FFPE) breast tumor tissue, and candidate gene expression was analyzed using the RNXtract® IVD and MammaTyper® IVD kits (BioNTech Diagnostics GmbH, Mainz) from 791 patients who participated in the FinHer trial. RNA levels of ESR1, PGR, HER2, and KI67 mRNA expression were measured using RT-qPCR,normalized according to the 40-DDCT method and compared with IHC or CISH results. Associations with distant disease-free survival (DDFS) and overall survival (OS) were assessed using the log-rank test.
Results: ESR1, PGR, HER2, and KI67 mRNA levels exhibited strong correlations with the respective clinical assays (each p-value <0.0001). The concordance rate of the mRNA assay and the clinical asssay was 92% for ESR1, 92% for HER2, 83% for PGR, and 68% for KI67 RNA. Using predefined cut-off values for ESR1, PGR, and KI67, the mRNA levels were prognostic for DDFS (p=0.002, p=0.005, and p=0.0005) and OS (p<0.0001, p=0.0001, and p=0.0024, respectively), whereas HER2 mRNA expression was not (p=0.17 and 0.11, respectively). Unexpectedly, the HER2 mRNA expression distribution of the ER-negative cancers was bimodal with little overlap between the HER2-low and HER2-high subsets, while in ER-positive cancers HER2 mRNA distribution was almost unimodal and in between the two subpopulations of ER-negative cancers. When different cut-offs were used for ER-positive and ER-negative cancers, tumor HER2 mRNA was also significantly associated with DDFS (p=0.031) and OS (p=0.018). Interestingly, 17% of ESR1 mRNA-negative and HER2 mRNA-negative patients exhibited high mRNA expression of PGR, and such patients had high 5-yr DDFS and OS (>95%).
Conclusions: Determination of ESR1, PGR, HER2, and KI67 without macrodissection of routine whole tissue FFPE specimens results in highly concordant results when compared to clinical assays. A significant minority of HER2 negative breast cancers expressed PGR mRNA despite low ESR1 mRNA levels and had superior outcome. HER2 mRNA levels differed substantially between ER-positive and ER negative tumors. This may explain why HER2 determination using a single cut-off for HER2 mRNA with the Oncotype DX assay frequently results in a false negative finding6. The MammaTyper-defined ESR1, PGR, HER2, and KI67 expression showed strong correlations with the corresponding clinical assays and survival.
1) Goldhirsch et al., Annals of Oncology 2013
2) Hammond et al., JCO 2010
3) Wolff et al., JCO 2007
4) Varga et al., PloS 2012
5) Polley et al., JNCI 2013.
Citation Format: Ralph M Wirtz, Pirkko-Liisa Kellokumpu-Lehtinen, Jorma Isola, Vesa Kataja, Petri Bono, Taina Turpeenniemi-Hujanen, Sirkuu Jyrkkiö, Harri Sitho, Sebastian Eidt, Ugur Sahin, Heikki Joensuu. Comparison of ESR1, PGR, HER2 and KI67 expression by central IHC and MammaTyper® RT-qPCR kit in the FinHer trial [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-02-01.
Collapse
Affiliation(s)
| | | | - Jorma Isola
- 3Laboratory of Cancer Biology, Institute of Medical Technology
| | | | | | | | | | - Harri Sitho
- 8Laboratory of Molecular Oncology, Biomedicum
| | | | - Ugur Sahin
- 10Institute of Pathology at the St-Elisabeth-Hospital
| | | |
Collapse
|
28
|
Wirtz RM, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen PL, Kataja V, Turpeenniemi-Hujanen T, Jyrkkiö S, Eidt S, Schmidt M, Joensuu H. Abstract P1-08-06: Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor immune cell infiltrates influence prognosis of node negative breast cancer (BC), and intratumoral B-cells and T-cells are of importance for achieving response to chemotherapy in triple negative BC. The role of tumor infiltrating macrophages remains unclear, but they might promote tumorigenesis. We investigated the prognostic value of CD68 mRNA levels within the luminal, HER2-positive and triple negative subtypes in the FinHer trial patient population, and evaluated their predictive value on survival outcomes achieved with adjuvant trastuzumab and chemotherapy in early breast cancer.
Methods: RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue of 917 (90.8%) patients out of the 1010 patients who participated in the FinHer trial. Intratumoral macrophage infiltration was assessed by measuring breast tumor CD68 mRNA content using RT-qPCR from representative FFPE tissue samples. Breast cancer molecular subtypes (luminal, HER2 positive and triple-negative) were approximated using immunohistochemistry (IHC) and central CISH testing data obtained from the FinHer trial datafile. Prognostic significance of CD68 on distant disease-free survival (DDFS) was assessed using Kaplan-Meyer analysis and log-rank test.
Results: Tumor CD68 mRNA expression was normally distributed with median expression of 33.56 (dCt). CD68 mRNA levels correlated weakly with estrogen receptor (ER) mRNA expression and ER protein levels (r = 0.11 and r = 0.15, respectively; p<0.0001), but not with tumor HER2 mRNA level or IHC/CISH status (r = -0.06, p = 0.12; and r = 0.01, p = 0.92, respectively). The median tumor CD68 mRNA content was not prognostic for DDFS in the subset of luminal cancers (ER+, HER2-; n = 533, 5-year DDFS 88% versus 88%; p = 0.92), but a lower than the median CD68 level tended to be associated with favorable DDFS in triple negative cancer (n = 143; 81% vs. 70%; p = 0.11) and was significantly associated with favorable DDFS in HER2-positive cancer (n = 191; 86% vs. 67%; p = 0.001). In the subset of HER2-positive cancer with tumor CD68 mRNA expression level lower than the median, patients treated with trastuzumab benefitted from addition of trastuzumab to chemotherapy (5-year DDFS 93% with trastuzumab vs. 79% without trastuzumab; p = 0.02), whereas no benefit from trastuzumab was observed when tumor CD68 content was higher than the median (67% vs. 68%; p = 0.92).
Conclusions: The study validates tumor CD68 concentration as a prognostic biomarker in HER2-positive early breast cancer. Patients with HER2-positive cancer and few tumor macrophages (low tumor CD68 mRNA content) benefitted from addition of trastuzumab to chemotherapy, whereas patients with HER2-positive BC with high tumor macrophage content derived no benefit from adjuvant trastuzumab. Trastuzumab may be effective only for macrophage-poor HER2-positive cancers that are prone to antibody-dependent cellular cytotoxicity (ADCC), whereas it may have little efficacy for cancers that progress despite or due to high intratumoral macrophage content that interferes with ADCC. Other agents, such as T-DM1, might work better than trastuzumab in the subset of women who have HER2-positive BC with a high tumor macrophage content.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-06.
Collapse
Affiliation(s)
- RM Wirtz
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - M Leinonen
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - P Bono
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - J Isola
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - P-L Kellokumpu-Lehtinen
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - V Kataja
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - T Turpeenniemi-Hujanen
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - S Jyrkkiö
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - S Eidt
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - M Schmidt
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| | - H Joensuu
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Institute of Medical Technology, Tampere, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital, Mainz, Germany
| |
Collapse
|
29
|
Wirtz RM, Aigner J, Marme F, Eidt S, Altevogt P, Sinn P, Schneeweiss A. Abstract P1-08-07: High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Immune cell infiltrates have been shown to play a prominent role with regard to prognosis of node negative breast cancer (Schmidt et al 2008). Moreover, it has been shown that B-cells and T-Cells are of particular importance for the response to chemotherapy (Schmidt et al. 2012). However, the role of macrophages remains unclear. It has been assumed, that tumor-associated macrophages play a role in promoting tumorigenesis. Still their role with regard to therapy prediction is unknown. Here we tested wether the infiltration of macrophages is associated with the response to neoadjuvant chemotherapy.
Materials and Methods
Pretreatment core cut biopsies from n = 100 patients with PBC treated within a randomized phase II trial (1) of anthracyline/taxane based NAC were examined. RNA from formalin-fixed, paraffin embedded (FFPE) routine biopsies were extracted using a bead-based extraction method (STRATIFYER XTRAKT kits). CD68 and ESR1, PGR, HER2, Ki67 as well as CALM2 as a house keeping gene were measured via a multiplex quantitative RT-PCR (RT-qPCR). Correlation analyses and partitioning tests were performed using the SAS JMP® 9.0.0 software.
Results
CD68 mRNA exhibited a normal data distribution (Median expression 40-DCT 34,66) in the core needle biopsies of advanced breast tumors. CD68 mRNA correlated strongly with Ki67 mRNA levels (Spearman r = 0,46; p<0,001), whereas there is virtually no correlation with other classical biomarkers such as ESR1, PGR and HER2. Partitioning analysis revealed that CD68 mRNA levels are superior to the previously and prospectively validated response markers ESR1 mRNA and HER2 mRNA. When using the median mRNA expression as an objective cut-off measurement no tumor having low CD68 mRNA expression did respond to chemotherapy, while 22% of the CD68 positive tumors responded by pathological complete response (ypT0ypN0). Based on molecular subtyping into Luminal, HER2 positive and Triple-Negative with predefined Cut-Off values for ESR1mRNA and HER2 mRNA levels, high CD68 were particularly informative within luminal tumors (22% pCR versus 0% pCR rate) and Triple negative tumors (38% pCR versus 0% pCR rate).
Conclusion
The presence of macrophages indicates tumors being sensitive to chemotherapy beyond the prospectively validated ESR1 and HER2 mRNA determinations (2), both in luminal and triple negative tumors. The mRNA expression levels of CD68 provide additional information beyond conventional subtyping and might therefore be useful for early assessment of non-response to chemotherapy und subsequent treatment planning.
1) Schneeweiss et al, Ann Oncol 2011
2) Denkert et al, Ann Oncol 2013.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-07.
Collapse
Affiliation(s)
- RM Wirtz
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - J Aigner
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - F Marme
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - S Eidt
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - P Altevogt
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - P Sinn
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| | - A Schneeweiss
- Stratifyer Molecular Pathology GmbH, Cologne, Germany; National Center for Tumor Disease (NCT), Heidelberg, Germany; Institute of Pathology at the St Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology of the University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
30
|
Rom J, Schumacher C, Gluz O, Höfler J, Eidt S, Domschke C, Marmé F, Nitz U, Sohn C, Schneeweiss A. Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers. Breast Care (Basel) 2013; 8:208-14. [PMID: 24415972 PMCID: PMC3728630 DOI: 10.1159/000352094] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND There is some controversy regarding the precise role and need for adjuvant therapy in patients with pT1a/pT1bN0 breast cancer, although studies have indicated that a HER2-positive status is one of the most powerful poor prognostic factors. PATIENTS AND METHODS We retrospectively evaluated disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) among 960 patients diagnosed between 2000 and 2008 with T1N0 primary breast cancer treated at 3 German centers, and determined prognostic risk factors. Univariate analysis was used to determine associations with potential risk factors. RESULTS With a median follow-up of 23 months, DFS was 94.8%, DDFS 96.3%, and OS 97.5%. Risk factors for decreased 1-year DFS were: peritumoral lymphatic invasion (L1) (p = 0.031), negative hormone receptor status (p = 0.003), non-use of hormonal therapy (p = 0.001), and a positive HER2 status (p = 0.003). Amongst the HER2-positive patients only 2.7% (n = 1/37) of those treated with trastuzumab had a DFS event compared with 20% (n = 10/50) without trastuzumab. CONCLUSION Patients with HER2-positive T1 breast cancer should be considered for inclusion in prospective trials of trastuzumab in combination with chemotherapy to determine the risk-to-benefit ratio and association with other prognostic factors.
Collapse
Affiliation(s)
- Joachim Rom
- Universitäts-Frauenklinik, Universität Heidelberg, Deutschland
| | | | - Oleg Gluz
- Brustzentrum, Bethesda Krankenhaus, Wuppertal, Deutschland
| | | | - Sebastian Eidt
- Institut für Pathologie, St. Elisabeth Krankenhaus, Köln, Deutschland
| | | | - Frederik Marmé
- Universitäts-Frauenklinik, Universität Heidelberg, Deutschland
- National Centrum für Tumorerkrankungen, Universität Heidelberg, Deutschland
| | - Ulrike Nitz
- Brustzentrum, Bethesda Krankenhaus, Wuppertal, Deutschland
| | - Christof Sohn
- Universitäts-Frauenklinik, Universität Heidelberg, Deutschland
| | - Andreas Schneeweiss
- Universitäts-Frauenklinik, Universität Heidelberg, Deutschland
- National Centrum für Tumorerkrankungen, Universität Heidelberg, Deutschland
| |
Collapse
|
31
|
Marme F, Schneeweiss A, Aigner J, Eidt S, Altevogt P, Sinn P, Wirtz RM. Abstract P3-06-08: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-06-08] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pathologic complete response (pCR, ypT0/is) is one of the strongest prognostic factors for primary breast cancer (PBC) in the setting of neoadjuvant chemotherapy (NAC). Factors predictive for response to NAC can help to stratify for an individualized therapy. As chemotherapeutic agents are most active in highly proliferative tumors, it was the aim of the present study to evaluate the potential of Ki-67 as a single proliferation marker, quantitatively measured on the mRNA or protein level, to predict response of PBC to NAC.
Material and methods: Pretreatment core cut biopsies from n=72 patients with PBC treated within a randomized phase II trial (1) of anthracylin/taxane based NAC were examined. Immunohistochemistry was performed for the Ki67 antigen on an automated IHC platform (Dako Techmate 500). Ki-67 were assessed either by visual scoring (vIHC) or by quantitative image analysis (qIHC). For quantitative IHC analysis tumor proliferation was analyzed after tumor stroma segmentation using the Aperio Image Analysis toolbox. RNA was extracted from formalin-fixed, paraffin embedded (FFPE) routine biopsies using a bead-based extraction method (STRATIFYER XTRAKT kits). Ki-67, TOP2A and RACGAP1 as well as CALM2 as a house keeping gene were measured via a multiplex quantitative RT-PCR (qPCR). Kaplan-Meier survival estimates, patitioning test and correlation analyses were performed using the SAS JMP® 9.0.0 software.
Results: There was only a moderate correlation between Ki-67 mRNA or Ki-67 measured by immunohistochemistry (IHC) and histologic grade (Spearman r = 0.52 p < 0.0001; r = 0.23 p = 0.033, respectively). Conventional visual scoring and qIHC correlated well (r = 0,78 p < 0,0001), while qPCR and qIHC correlated moderately (r = 0,50 p < 0,0001). For Ki-67 determined by visual scoring of standard IHC there was an optimal discrimination at a cut-off of 20% stained nuclei with regard to chemotherapy response. Yet, the difference between pCR-rates for high and low Ki-67 on IHC was non-significant, with 16.3% and 12.5% pCRs in the IHC Ki-67 high and low group, respectively. For Ki-67 IHC analysed by quantitative image analysis there was optimal cut-off at 35% stained nuclei resulting in 37,5% versus 8,7% pCR rate and 54% of pCRs classified correctly. For qPCR determination, high Ki-67 mRNA expression was associated with a high pCR-rate of 36.4% as opposed to 5.8% in tumors with low Ki-67 mRNA levels and 82% classified correctly.
Conclusion: High Ki-67 mRNA expression measured by RT-qPCR was predictive for the achievement of pCR to NAC and in this respect was superior to Ki-67 determined by vIHC or qIHC. This is consistent with data on Ki-67 IHC as a predictor of pCR on larger neoadjuvant cohorts (1). RT-qPCR based measurements of Ki-67 mRNA ensures an objective and highly reproducible quantification of proliferative activity from FFPE tissue from routine core cut biopsies. As such it seems to be more robust and meaningful compared to protein-based determination of Ki-67 by IHC, both by visual scoring or quantitative image analysis.
1) Schneeweiss et al, Ann Oncol 2011 2) Fasching et al., BMC Cancer 2011
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-06-08.
Collapse
Affiliation(s)
- F Marme
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - A Schneeweiss
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - J Aigner
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - S Eidt
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - P Altevogt
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - P Sinn
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| | - RM Wirtz
- National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany
| |
Collapse
|
32
|
Hartmann A, Bertz S, Keck B, Dyrskjot L, Orntoft T, Wullich B, Hake R, Eidt S, Wirtz R. Abstract 3654: Prognostic role of androgen receptor in bladder cancer. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-3654] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aims: Hormone receptors are the prototype predictive marker in breast and prostate cancer. Hormone receptor positive cancers have a better prognosis, increased tropism to metastasize into the bones and respond to endocrine treatment options. The prognostic value of hormone receptor in urothelial carcinoma of the bladder (UCB) is less established. This may in part result from technical limitations of immunhistochemical detection methods. Interestingly, female gender has recently been identified as strong adverse factor in advanced UCB (May et al., 2011). By analyzing whole genome expression data from non-muscle invasive bladder cancer patients, we have evaluated the potential of top candidate genes (ESR1, PGR, AR, CYP19, HER2, RACGAP1) commonly used to stratify breast cancer patients to predict bladder cancer progression. In view of the gender specific effects, we have focused on the prognostic role of androgen receptor expression on tumor invasion, disease progression and survival. Methods: Affymetrix microarray data from 41 non-metastatic bladder cancer patients undergoing curative surgery were analyzed. Prognostic value of androgen receptor mRNA expression was analyzed by unsupervised Cluster analysis, partitioning tests, Mann Whitney tests and Kaplan Meier estimates of cancer specific survival. Results: Cluster analysis in the microarray date of the superficial UCB cohort identified a hormone receptor positive subtype and a proliferation dominated subtype of equal size. Androgen receptor expression was negatively associated with cancer specific death (r=−0,42; p=0,005), while proliferation correlated with increased risk of cancer specific death (r=0,46; p=0,003). In addition, low androgen receptor expression was associated with higher tumor stage (pTa vs pT1-4; p=0,017). In Kaplan Meier analysis, the cancer specific survival was significantly better in tumors exhibiting high androgen receptor levels (80% vs. 20 %; p<0,0001). Discussion: Resembling to some extent the situation in other cancer types, hormone receptors are prognostic factors in early stage bladder cancer. These results may also explain the recently described gender specific effects in bladder cancer. Moreover, these results raise the possibility, that UCB patients may be stratified according to their androgen receptor status in view of prognosis and putative endocrine therapy options.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3654. doi:1538-7445.AM2012-3654
Collapse
Affiliation(s)
| | | | | | | | | | | | - Roland Hake
- 3St Elisabeth Krankenhaus Cologne, Cologne, Germany
| | | | | |
Collapse
|
33
|
Wirtz RM, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen PL, Kataja V, Turpeenniemi-Hujanen T, Jyrkkiö S, Huang W, Eidt S, Joensuu H. P2-12-04: RACGAP1 mRNA Assay Outperforms Ki-67 as a Proliferation Marker in the FinHer Study Cohort. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Molecular subtyping of breast cancer has become an integral part of standard evaluation of breast cancer patients. Their assessment requires combining data from analyses on ER, PR, HER2 and cell proliferation markers. However, their immunohistochemical (IHC) testing carries an up to 20% risk of erroneous results. Similarly, assessment of cell proliferation by Ki-67 staining is hampered by lack of standardization of laboratory methods and agreement on cut-offs. Here we tested the prognostic value of objective quantitation of ESR1, PgR, HER2 and the proliferation markers RACGAP1 using RT-qPCR and compared the results with local and central IHC assessments.
Methods: RNA was extracted from FFPE tumor tissue of 917 patients who participated in the FinHer trial. ESR1, PgR, HER2 and RACGAP1 mRNA expression were measured using RT-qPCR. The molecular subtypes (luminal, HER2−enriched and triple-negative) were determined. Prognostic significance of proliferation markers was assessed using univariate and multivariate analyses. The RT-qPCR results were compared with local and central IHC results.
Results: HER2 mRNA showed a bimodal distribution with 197 (21.4%) out of the 917 tumors being above the predefined cut-off. HER2 mRNA expression increased in parallel with HER protein expression. Overall concordance of HER2 mRNA testing with central IHC and CISH was good, while local IHC testing suffered higher false positive rates. RACGAP1 mRNA expression was the greater the higher the histological grade. ESR1 and PgR mRNA correlated negatively with the histological grade (r=-0.38 and r=-0.33; p<0.0001), whereas HER2 and RACGAP1 mRNA were correlated positively (r=0.10 and r=0.49; p=0.002 and p<0.0001, respectively). RACGAP1 mRNA was negatively associated with ESR1 and PgR mRNA (r=-0.17 and r=-0.26, respectively; p<0.0001 for each). Molecular subtypes determined by RT-qPCR using predefined cut-off values were highly prognostic for overall survival (OS) (p<0.001). The 5-year OS rate for patients with luminal cancer was 94% and 86% for HER2−enriched cancer and 84% for triple-negative cancer. In the subset of luminal tumors, high expression of RACGAP1 identified a population of patients who were at a high risk of death (5-year OS 82% versus 95%; p<0.0001). In a multivariate analysis RACGAP1 mRNA expression, nodal status and chemotherapy type were independent prognostic factors, whereas IHC of ER, PgR, Ki-67 and histological grade were not significant.
Conclusions: Molecular subtyping of breast cancer by RT-qPCR using RNA isolated from FFPE tissue proved successfully in this large patient cohort. RACGAP1 mRNA expression distinguished high and low risk luminal breast cancers. In a multivariate analysis mRNA-based molecular markers outperformed the immunohistochemical markers ER, PgR and Ki-67. Of note, quantitative assessment of the proliferation marker RACGAP1 was superior to semiquantitative assessment of Ki-67 from routine FFPE tissues using IHC. We conclude that quantitative assessment of ESR1, PgR, HER2 and RACGAP1 mRNA by RT-qPCR is a robust and reproducible method to assess these key tumor biological factors from archival FFPE tumor tissue. RACGAP1 is novel cell proliferation marker in breast cancer that warrants further validation.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-04.
Collapse
Affiliation(s)
- RM Wirtz
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - M Leinonen
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - P Bono
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - J Isola
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - P-L Kellokumpu-Lehtinen
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - V Kataja
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - T Turpeenniemi-Hujanen
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - S Jyrkkiö
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - W Huang
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - S Eidt
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| | - H Joensuu
- 1STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Finland; Helsinki University Central Hospital and University of Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Finland; Kuopio University Hospital, Finland; Oulu University Hospital, Finland; Turku University Hospital, Finland; Monogram Biosciences, Inc.; Institute of Pathology at the St-Elisabeth-Hospital, Germany
| |
Collapse
|
34
|
Rom J, Schumacher C, Gluz O, Zuna I, Eidt S, Marmé F, Nitz U, Sohn C, Schneeweiss A. Bedeutung und Prognose des Her2/neu-Rezeptors in primären Mammakarzinomen <2cm (T1). Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
35
|
Brueckl WM, Eschbach C, Wiest GH, Ficker JH, Zirlik S, Hake R, Eidt S, Hartmann A, Wirtz RM. Influence of expression of estrogen (ERS-1) and progesterone (PGR) receptors on metastatic spread and outcome in non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7585] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Ricke A, Schumacher C, Hindrichs N, Eidt S, Jennissen J. 11 poster lORT WITH ELECTRONIC BOOST IN THE TUMORBED PRIOR TO POSTOPERATIVE WBRT AS STANDARD PROCEDURE UNICEN-TRIC BREAST CANCER. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70134-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Schneeweiss A, Schumacher C, Gluz O, Zuna I, Eidt S, Marme F, Nitz U, Sohn C, Rom J. Association of HER2 overexpression and prognosis in small primary breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Diederich S, Eidt S, Lüthen R. [Multiple bilateral pulmonary nodes following breast cancer]. Dtsch Med Wochenschr 2009; 134:981-4. [PMID: 19401963 DOI: 10.1055/s-0029-1222554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
HISTORY AND ADMISSION FINDINGS Multiple new pulmonary nodules were demonstrated at chest radiography in a 69-year-old woman who had been treated for breast cancer ten years previously. INVESTIGATIONS Laboratory tests suggested mild inflammation. Pulmonary function tests demonstrated small airways disease. But because of an atypical morphology at computed tomography (CT), metastases were considered unlikely. CT-guided percutaneous biopsy revealed cryptogenic organizing pneumonia (COP). TREATMENT AND COURSE Oral medication with decreasing doses of steroids resulted in clinical and radiological improvement. CONCLUSIONS Even in a patient with known malignancy the differential diagnosis of multiple bilateral pulmonary nodules includes a variety of conditions and is meticulous, if necessary invasive diagnostic procedures are required.
Collapse
Affiliation(s)
- S Diederich
- Institut für Diagnostische und Interventionelle Radiologie / Nuklearmedizin, Marien Hospital Düsseldorf.
| | | | | |
Collapse
|
39
|
Eidt S, Jergas M, Schmidt R, Siedek M. Metastasis to the pancreas--an indication for pancreatic resection? Langenbecks Arch Surg 2007; 392:539-42. [PMID: 17242893 DOI: 10.1007/s00423-007-0148-7] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2006] [Accepted: 12/06/2006] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND AIMS Isolated metastatic involvement of the pancreas is very rare. To evaluate the possible benefit of surgery, we retrospectively analyzed patients that underwent pancreatic resection for metastases into the pancreas. PATIENTS/METHODS In 12 patients (8 men and 4 women), metastatic disease was treated by pancreatic resection (two total pancreatectomies, nine pylorus-sparing duodenopancreatectomies, and one left-side pancreatic resection) between 1993 and 2005 at our institution. Primary malignomas were renal cell carcinoma (RCC; n = 7), malignant melanoma (n = 4), and colon cancer (n = 1). All patients were followed-up until November 2006 or until death. RESULTS Complications requiring relaparotomy were found in two patients (retroperitoneal abscess and bile fistula), whereas one patient with pancreatic fistula could be treated by conservative measures. There was no perioperative mortality. Median survival time was 51 months (5-105 months). At the end of follow-up, seven patients were alive at 12 to 86 months, whereas five died between 5 and 105 months: four died of the disease, and one patient died of cardiac failure without evidence of recurrent cancer. CONCLUSION Patients with isolated pancreatic metastasis particularly of RCC benefit from surgery. Pancreatic resection may achieve long-term survival or good palliation in selected cases of other primaries as well.
Collapse
Affiliation(s)
- S Eidt
- Institute of Pathology, St. Elisabeth-Hospital Cologne, Werthmannstrasse 1, 50935, Cologne, Germany.
| | | | | | | |
Collapse
|
40
|
Clarke GM, Eidt S, Sun L, Mawdsley G, Zubovits JT, Yaffe MJ. Whole-specimen histopathology: a method to produce whole-mount breast serial sections for 3-D digital histopathology imaging. Histopathology 2007; 50:232-42. [PMID: 17222252 DOI: 10.1111/j.1365-2559.2006.02561.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIMS To develop a method for preparing diagnostic-quality, whole-mount serial sections of breast specimens while preserving 3-D conformation. This required supporting the fresh specimen prior to breadloafing and refining the conventional tissue processing method. The overall goal is to use digital images of whole-specimen histopathology to improve the estimation of extent of disease. METHODS AND RESULTS To maintain a 3-D conformation, the specimen is suspended in 3.5% agar at 55 degrees C. The block is sliced at 5-mm intervals. Sectioning is performed after extended fixation in 4% formaldehyde from paraformaldehyde in 0.1 m Millonig's buffer, followed by paraffin processing using a non-routine schedule and extended paraffin infiltration. Whole-mount serial breast sections are produced with features of equal or superior quality to that which can be achieved using conventional methods. The method is compatible with some immunohistochemical stains but requires further optimization for others. CONCLUSIONS The technique is currently suitable for research applications. With the reduction in processing time achievable with microwave-assisted processing, there is the potential for its use as a routine clinical method. This tool may improve the accuracy of margin estimates and identification of multifocality in breast cancer; further evaluation is necessary.
Collapse
Affiliation(s)
- G M Clarke
- Imaging Research, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada.
| | | | | | | | | | | |
Collapse
|
41
|
Diederich S, Eidt S. Lungenbiopsie. ROFO-FORTSCHR RONTG 2007. [DOI: 10.1055/s-2007-976607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
Diederich S, Padge B, Vossas U, Hake R, Eidt S. Application of a single needle type for all image-guided biopsies: results of 100 consecutive core biopsies in various organs using a novel tri-axial, end-cut needle. Cancer Imaging 2006; 6:43-50. [PMID: 16766268 PMCID: PMC1693774 DOI: 10.1102/1470-7330.2006.0008] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Purpose: To assess feasibility, results and complications in image-guided biopsies using a single needle design in various organs. Materials and methods: 100 consecutive percutaneous biopsies were performed in 54 females and 46 males aged 24–87 years (mean age/standard deviation: 64.5 +/− 12 years) using a full-core end-cut tri-axial full-automatic biopsy needle (18 gauge BioPince ™, InterV-MDTech, Gainesville, Florida) under CT (n=45) or ultrasound (n=55) guidance. In 63 biopsies a coaxial technique was used. Results: Biopsies were obtained of liver (n=32), lymph nodes (n=17), thyroid (n=11), lung (n=9), adrenal (n=9), pelvis (n=6), chest wall/pleura (n=6), mediastinum (n=4), lytic bone lesions (n=2), retroperitoneum (n=1), muscle (n=1), pancreas (n=1), peritoneum (n=1). Between 1 and 6 (mean/SD 2.83 +/− 0.92) needle passes were performed. In 77 cases a malignant (40 metastases, 37 primary tumours) and in 23 a benign lesion was diagnosed. Of the 23 benign lesions a specific diagnosis was possible in 22. In one case necrosis and haemorrhage was diagnosed. In this patient surgery and autopsy both revealed a mediastinal haematoma of unknown origin. Eight minor complications (mild pain/local haematoma requiring no therapy) and three major complications (three pneumothoraces in nine lung biopsies requiring two aspirations and one drainage) were observed. There was no mortality. Conclusion: Percutaneous image-guided biopsy using the described full-core end-cut needle resulted in a specific diagnosis in 99/100 consecutive biopsies in various organs with a low complication rate. We use this needle type for all CT- or US-guided biopsies in all organs except for solid bone.
Collapse
Affiliation(s)
- S Diederich
- Department of Diagnostic and Interventional Radiology/Nuclear Medicine, Marien Hospital, Düsseldorf, Germany.
| | | | | | | | | |
Collapse
|
43
|
Pohl C, Eidt S, Kruis W. [Microscopic colitis]. Dtsch Med Wochenschr 2005; 130:1962-7. [PMID: 16123901 DOI: 10.1055/s-2005-872611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- C Pohl
- Innere Abteilung, St. Elisabeth Krankenhaus, Köln.
| | | | | |
Collapse
|
44
|
Diederich S, Eidt S. Perkutane Lungenbiopsie: einfach, sicher, diagnostisch. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-867290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
45
|
Diederich S, Padge B, Hake R, Vossas U, Eidt S. Ergebnisse der perkutanen Schneidbiopsie mit einem neuartigen vollautomatischen triaxialen Biopsiesystem in verschiedenen Organen. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-868284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Bastian PJ, Eidt S, Koslowsky TC, Wulke AP, Siedek M. Duodenal somatostatinoma: clinical and immunohistochemical patterns--difficult differential diagnosis in regard to gangliocytic paraganglioma: report of a case. Eur J Med Res 2005; 10:135-8. [PMID: 15851380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023] Open
Abstract
The authors report a large duodenal somatostatinoma, a very rare tumor entity. A 8.5 cm globular mass in the area of the unicate process of the pancreas was detected in a 45 year old caucasian female by computerized tomography. The patient had only mild complaints. Initial treatment consisted of right pancreatectomy with preservation of the pylorus. Histological evaluation rendered a diagnosis of low-grade malignant neuroendocrine carcinoma with expression of somatostatin, respectively of somatostatinoma arising in the duodenum and infiltrating into the pancreas. 26 months after the initial surgery liver and lymph node metastases were detected and surgically removed. This case confirms that duodenal somatostatinomas are very difficult to diagnose preoperatively because of unspecific symptoms. Most duodenal somatostatinomas are found incidentally. Treatment of choice is radical surgical resection with a possible cure in early stages of the disease. Even a large tumor as ours is resectable with negative surgical margins. Management of recurrent or metastatic disease is also surgical. Additional chemotherapy and supportive care may be beneficial for the patient.
Collapse
Affiliation(s)
- Patrick J Bastian
- Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Rheinische Friedrich-Wilhelms Universität, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany.
| | | | | | | | | |
Collapse
|
47
|
Jergas M, Walter H, Eidt S, Eidt H, Wilhelm T, Siedek M. Gastrointestinale Stromatumoren – radiologisch-pathologische Korrelation. ROFO-FORTSCHR RONTG 2004. [DOI: 10.1055/s-2004-827827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Abstract
BACKGROUND Since primary malignant lymphomas of the liver represent a rare entity, no commonly accepted therapeutic strategy has been developed so far. CASE STUDY We report the case of a diffuse large-cell B-cell lymphoma of the liver in a 48-year-old female patient. The tumor presented as a solitary mass measuring 12.5 cm in maximum diameter. After neoadjuvant chemotherapy, the lymphoma was completely resected (R0). A massive therapy-induced tumor regression was found histologically. No involvement of regional lymph nodes or other organs was detected during staging procedures (stage I EA). After six courses of adjuvant chemotherapy, the patient has been alive and well for more than 5 years and shows no evidence of tumor relapse. CONCLUSION This case documents the effect of systemic chemotherapy on lymphoma cells. In many centers systemic chemotherapy is used as the only therapeutic regimen. Neoadjuvant chemotherapy might, however, represent an important addition to the therapeutic strategies concerning unilocular primary hepatic lymphomas.
Collapse
Affiliation(s)
- Sebastian Eidt
- Institut für Pathologie, St.-Elisabeth-Krankenhaus, Köln-Hohenlind, Cologne.
| | | | | | | |
Collapse
|
49
|
Schreiber FS, Eidt S, Hidding M, Schmidt-Walczuch J, Werning C. Collagenous duodenitis and collagenous colitis: a short clinical course as evidenced by sequential endoscopic and histologic findings. Endoscopy 2001; 33:555. [PMID: 11437054 DOI: 10.1055/s-2001-14968] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- F S Schreiber
- Department of Medicine, St Katharinen Teaching Hospital, University of Cologne Medical School, Frechen, Germany.
| | | | | | | | | |
Collapse
|
50
|
Wagner M, Klussmann JP, Fangmann R, Linder R, Elewa ME, Eidt S, Rose VM, Jungehulsing M, Schulze HJ. Cyclin-dependent kinase-inhibitor 1 (CDKN1A) in the squamous epithelium of the oropharynx: possible implications of molecular biology and compartmentation. Anticancer Res 2001; 21:333-45. [PMID: 11299759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The cdknlA gene encodes CDKN1A, a protein that regulates cell cycle progression, terminal differentiation, and apoptosis. Polymorphisms or loss of heterozygosity of this usually biallelically expressed gene have no major impact on carcinogenesis. The prevalence of somatic mutations in malignancies is low. Gene rearrangements involving cdknlA are scarce. CDKN1A is expressed in both premalignant and malignant lesions. While the prognostic value of nuclear CDKN1A expression is controversial, the prognostic value of its recently discovered cytoplasmic accumulation is simply unknown. CDKN1A translocates from the nucleus to the cytoplasm when cleaved by caspase-like activities during early apoptosis. The presence of cytoplasmic catabolites (e.g.: p14) might therefore indicate apoptosis. We found no correlation between nuclear and cytoplasmic anti-CDKN1A immunoreactivity in our samples of oropharyngeal squamous cell carcinoma. CDKN1A Cap20, CDKN1, CDKN1A, CDKNA1, Cip-1, Mda-6, P21, Pic1, Sdi-1, Waf-1.
Collapse
Affiliation(s)
- M Wagner
- Department of Pathology, University of Cologne Medical School, Cologne, FRG
| | | | | | | | | | | | | | | | | |
Collapse
|